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ABSTRACT
INVESTIGATING THE MODULATION AND MECHANISMS OF α7 NICOTINIC
ACETYLCHOLINE RECEPTORS IN NICOTINE DEPENDENCE

By Asti B. Jackson

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2017

Major Director: M. Imad Damaj, PhD, Professor, Pharmacology and Toxicology

Tobacco dependence dramatically increases health burdens and financial costs. Limitations of
current smoking cessation therapies indicate the need for improved molecular targets. Nicotine,
the main addictive component of tobacco, exerts its dependency effects via nicotinic
acetylcholine receptors (nAChRs). The homomeric α7 nAChR is one of the most abundant
receptors found in the brain and has unique features in comparison to other nAChR subtypes
such as high calcium permeability, low probability of channel opening, and a rapid
desensitization rate. α7 nAChR agonists reduce nicotine's rewarding properties in the
conditioned place preference (CPP) test and i.v. self-administration. Recently, the peroxisome
proliferator-activated receptor type-α (PPARα) has been implicated as a downstream signaling
target of the α7 nAChR in ventral tegmental area dopamine cells. It is unknown whether the
intrinsic characteristics of the α7 nAChR and PPARα are involved in its attenuation of nicotine
reward. Therefore, this dissertation sought to investigate the role of α7 nAChRs in a mouse

xiii
model of nicotine CPP and nicotine withdrawal by 1) investigating the impact of
pharmacological modulation of α7 nAChR function in nicotine dependence and 2) evaluating a
possible role for PPARα as a downstream mediator of α7 nAChRs in nicotine dependence.
Positive allosteric modulators (PAMs) and a silent agonist were used to investigate the role of α7
nAChR conformations. The utilization of the α7 nAChR Type I PAM NS1738, Type II PAM
PNU120596, and silent agonist NS6740 provided insight about the probability of channel
opening (NS1738, PNU120596), desensitization (PNU120596, NS6740), and modulation of the
endogenous acetylcholine/ choline tone (NS1738, PNU120596) as it relates to the α7 nAChR in
nicotine CPP and withdrawal. In addition, this dissertation sought to elucidate the role of the α7
nAChR and PPARα in nicotine dependence using pharmacological interventions. The results
suggest that the role of the α7 nAChR in nicotine dependence is conformation-dependent and
PPARα-mediated. This dissertation is the first to report PPARα-mediation of the effects of α7
nAChR in nicotine reward and attenuation of nicotine withdrawal signs by PPARα activation.
This data supports the development of α7 nAChR agonists and PPARα activators as possible
smoking cessation aids.

CHAPTER ONE
GENERAL INTRODUCTION

A. Nicotine Dependence
Tobacco dependence remains one of the leading sources of preventable death worldwide 1,2. In
the United States alone, approximately 550,000 deaths are caused by smoking-related diseases
such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes and 12 types of
cancers 3. In particular, it is estimated that 80% of lung cancer cases are caused by smoking 4.
The economic burden of smoking is over $280 billion dollars annually (including smokingrelated health costs and productivity losses)5. Although the rate of smoking has declined (20.9%
in 2005 to 15.1% in 2015)6, there are still about 40 million individuals who engage in tobacco
use in the United States7. There are possible explanations that can account for this continued
tobacco use. The perpetuation of tobacco use may be due to the switching of traditional tobacco
products such as cigars and cigarettes to smokeless tobacco products, hookah and e-cigarettes8.
This transition to newer tobacco products is thought to be driven by the reduced harm perception
of these products compared to cigarettes 9. Due to the limited scientific evidence available, it is
unclear whether e-cigarettes have any long-term harmful effects or can act as smoking cessation
treatment 10. In addition, there is a growing concern that e-cigarette use may normalize smoking
behaviors and promote the use of traditional tobacco products11. This is even more alarming
since e-cigarette use has doubled in adolescents in recent years8. Smoking initiation during
adolescence is another factor that may sustain tobacco-smoking rates nationally. Adolescence is
a unique period marked by considerable neurobiological changes12,13 risking taking behavior14
and experimentation with drugs of abuse including tobacco products5. In addition, drug use
1

during adolescence is a predictor for substance abuse in adulthood. It is estimated that 90% of
adult smokers have reported having their first cigarette before age 18 5. Another explanation for
the continued tobacco use may lie with the modest success rate of current smoking cessation
therapies with less than 30% of individuals remaining abstinent for more than 1 year

15

. The

current smoking cessation aids (varenicline , bupropion, and nicotine replacement therapies) all
share a common mechanism of action by interacting with nicotinic acetylcholine receptors
(nAChRs)

16,17

. Varenicline (Chantix® ) is marketed as a high affinity α4β2* (* denotes the

inclusion of other subunits in the receptor) nAChR partial agonist with other targets including the
α7 nAChRs and α3β4* nAChRs where it acts as a full agonist18,19. Bupropion is an FDAapproved antidepressant marketed under the name Wellbutrin XL® and is also indicated as a
smoking cessation aid (Zyban®)20. Its mechanisms of action include dopamine reuptake inhibitor
21

and noncompetitive antagonist of α3β2, α4β2*, and α7 nAChRs22–25. Nicotine replacement

therapies such as the nicotine patch (NicoDerm CQ®) partially replace nicotine at nAChRs in an
attempt to relieve withdrawal symptoms26. The modest efficacy of the current smoking cessation
aids raises the need for a better understanding of the complex neurobiology underlying nicotine
dependence. This in turn will aid in the discovery of new molecular targets and the development
of more effective treatments.

B. Nicotine and Nicotinic Acetylcholine Receptors
Cigarette smoke has over 4,000 components27; however, nicotine is thought to primarily
mediate the rewarding effects of tobacco. Nicotine has been shown to have reinforcing and
positive subjective effects in humans

28,29

. Nicotine is also self-administered in rodents30–32 and

non-human primates33,34 and induces a preference in the conditioned place preference test35–37.

2

Nicotine mediates its effects through nAChRs38 which belong to the Cys-loop receptor family
and are ligand gated ion channels that form pentamers arranged around a water-filled pore39,40.
The subunits of mammalian neuronal nAChRs range from α2-α7, α9, α10 and β2-β4. These
receptors are permeable to both Na+ and Ca2+ and can form homomeric and heteromeric
receptors41. Nicotinic subunits can assemble in different combinations resulting in a diversity of
functions of nAChR subtypes. These receptors have three broad conformational states: resting
closed states, open states, and desensitized states

42

. The typical resting closed state is induced

when the orthosteric site (traditional ligand binding site) is unoccupied and the cation channel is
closed. Upon binding of an orthosteric agonist, the cation channel is opened which allows the
influx of cations into the cell. Following the open state the receptor is then desensitized; despite
agonist binding the cation channel is closed rendering the receptor inactive43. However, there are
new compounds known as “silent agonists” that do not behave as typical orthosteric agonists.
Silent agonists are orthosteric agonists that do not cause channel opening after binding, but
instead promote conformational changes associated with the desensitized state44–46. nAChRs are
located pre-, post and extrasynaptically throughout the central nervous system
in fast synaptic transmission and modulation of neurotransmitter release

48

47

where they aid

. The most abundant

nicotinic receptors found in the mammalian brain are the nicotinic low affinity homomeric α7
and the nicotinic high affinity heteromeric α4β2*49. These two classes of nAChRs have diverse
characteristics. The α7 nAChR has high calcium permeability, low probability of opening, rapid
desensitization (in milliseconds) and binds α-bungarotoxin50,51. In contrast, the α4β2* nAChR
has a high probability of opening, desensitizes at a slower rate (in seconds) and does not bind αbungarotoxin52. nAChRs, like most proteins, have orthosteric binding sites (traditional agonist
binding sites) and allosteric binding sites (nontraditional agonist binding sites)53,54. This has

3

allowed for the development of pharmacological tools that can induce activation of nAChRs via
various mechanisms. Positive allosteric modulators (PAMs) bind to the allosteric site of nAChRs
and enhance the efficacy of endogenous agonists (acetylcholine and choline) and the probability
of channel opening, decrease the rate of desensitization, and increase the affinity of ligands
without having an effect on their own42,55,56. Pharmacological interventions along with
preclinical animal models of nicotine reward and withdrawal will further the understanding of
the underlying mechanisms of nicotine dependence.

C. Preclinical Models for Measuring Nicotine Dependence

Animal models are invaluable to drug abuse research. Research conducted with animal subjects
can be controlled for variables and allow for thorough investigation of underlying mechanisms57.
There are multiple models used to assess various aspects of nicotine dependence in rodents and
nonhuman primates such as reward, reinforcement and withdrawal. Self-administration is a
model of drug reinforcement that is thought to mimic drug seeking and drug taking behavior in
humans 58. With the exception of hallucinogens, drugs that are abused in humans are typically
self-administered in animal models given it a high degree of face validity and predictive validity
59

. Nicotine self-administration has even been demonstrated in humans in a laboratory setting 28.

In this operant conditioning paradigm nonhuman subjects range from monkeys to rodents and the
typical drug reinforced behaviors include lever presses and nose pokes for rodents and a panel
press response for nonhuman primates57. The delivery of the drug can vary from oral,
intramuscular, and most commonly via intravenous catheterization. In the case of nicotine, the
primary route of administration in humans is through inhalation which produces a rapid onset of

4

action; therefore, the most desirable and controlled drug delivery method that allows for a rapid
onset for nicotine self-administration in rodents is intravenous catheterization32.
Drug discrimination is a paradigm that classifies and categorizes drugs based on their
interoceptive effects

60

. Commonly abused drugs in humans produce interoceptive effects that

may contribute to their abuse liability. Abused drugs that produce discriminative effects in
animals produce subjective effects in humans

61,62

including nicotine

63

. However, drugs that

have no abuse liability, such as the atypical antipsychotic drug clozapine

64

, can produce

discriminative stimulus effects 60. Drug discrimination has predictive validity for CNS-mediated
compounds

65

. This technique consists of a food reinforced operant response of a lever press or

nose poke in the case of rodents. During training sessions, rodents are pretreated with drug or
vehicle and the correct lever press results in food pellet presentation. Drug discrimination
investigates whether other drugs produce similar interoceptive effects as the training drug or
whether another compound can augment the interoceptive effects of the training drug 66.
Intracranial self-stimulation (ICSS) is a model of operant conditioning that measures abuse
liability of drugs. A monopolar or bipolar electrode is implanted in brain regions such as the
medial forebrain bundle. Medial forebrain bundle excitation produces stimulation of the
mesolimbic pathway (pathway associated with reward)67.The electrical stimulation from the
electrode reinforces a behavioral response such as lever presses in rodents68. The frequency or
amplitude of electrical stimulation can be manipulated. Drugs of abuse are said to ‘facilitate’
ICSS if the drug causes a leftward shift of ICSS stimulation frequency-rate curves and decrease
ICSS thresholds 69. Nicotine along with other drugs of abuse facilitate ICSS stimulation 70. Druginduced ICSS facilitation is thought to correlate with drug abuse potential in humans giving this
model predictive validity 68.
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Conditioned place preference (CPP) is a Pavlovian conditioning paradigm used to asses drug
reward

71

. CPP involves associative learning where animals are thought to pair the rewarding

effects of a drug (unconditioned stimulus) with the context the drug was once received
(conditioned stimulus). This drug-induced association is clinically relevant. It has been reported
that exposure to drug-related cues in dependent users induces drug cravings

72

. In particular,

smoking cues such as a burning cigarette or a lighter associates with rewarding effects induced
by nicotine which perpetuates smoking behavior in humans73,74. Smoking cues not only induce
cravings that can reinforce smoking but also induce physiological responses such as increased
blood pressure and heart rate 75,76. Drugs abused in humans induce a preference in the CPP test in
animal models giving the model predictive validity. The CPP test has also been performed in
humans77.
a. Conditioned Place Preference Methods
Our lab uses an unbiased, counterbalanced and randomized CPP protocol. In the typical CPP
test, there are a set of distinct contextual cues. Our CPP apparatus has three chambers in a linear
arrangement. The white external chamber (visual cue) consists of a mesh floor texture (tactile
cue) and the black external chamber (visual cue) has a rod floor texture (tactile cue). The
external chambers are separated by a smaller gray chamber with a smooth PVC floor. Mice are
then conditioned with drug or vehicle in the white or black chambers. On baseline day mice are
free to roam all three chambers, the time spent in the white, and black chambers are recorded. On
conditioning days after drug injection mice are confined to one compartment for 20 min and 4
hrs. later they were confined to the other compartment with the injection they did not receive in
the morning session (be that vehicle or drug). On test day, mice are allowed access to all
chambers for 15 min in a drug free state. The preference score was calculated by determining the
6

difference between the time spent in the drug paired side during test day versus the time in drugpaired side during the baseline day. The nicotine CPP paradigm has been well established by our
lab and others

36,37,78,79

. Nicotine has a narrow dose response curve in the CPP test and the dose

of 0.5mg/kg of nicotine that is typically used in our studies has been shown to induce a
significant preference in mice in the CPP test78,80. CPP has some limitations that could be
considered potential confounding factors for the interpretation of the results (locomotor activity
changes, novelty-seeking behavior on test day, and contextual preferences for one side or the
other). To address the potential effect that drugs may have on locomotor activity, our CPP boxes
are equipped with infrared beams that measure the locomotor activity of animals during the test.
During the test day, animals are in a drug free state and there are typically no differences
observed of locomotion between treatment groups. Also, mice naturally explore novel areas or
objects

81

. To address this possible confound our boxes are 3-chamber compartments (with a

central compartment), which limits the impact of novelty-seeking behavior on test day. The most
novel chamber is the center chamber that is not paired with drug or vehicle. Mice are only
exposed to this chamber on baseline and test day whereas they are exposed to the other chambers
throughout the duration of the experiment. In addition, our extensive work with mice on an ICR
background over the years in the CPP test showed that this propensity for contextual preference
is rare in this strain, and any mouse showing preference for one side higher than 65% on the
baseline day was not used in the study.
Nicotine withdrawal is one aspect of nicotine dependence that is considered to be a negative
reinforcer for perpetuating tobacco use 29. The current smoking cessation therapies are thought to
attenuate this important component of nicotine dependence82. Nicotine withdrawal symptoms in
humans consist of physical signs (bradycardia, gastrointestinal discomfort, increased appetite),

7

cognitive signs (difficulty concentrating, impaired memory), and affective signs (anxiety,
depressed mood, anhedonia)

83,84

. Rodents serve as a model to investigate nicotine withdrawal.

To mimic human nicotine exposure, rodents receive chronic nicotine via various routes of
administration such as orally 85,86, intravenous infusion 87, subcutaneous (s.c.) minipump (MP) 88–
90

, and chronic systemic injections

91,92

. Nicotine withdrawal is induced either spontaneously

(removal of chronic nicotine) or precipitated via the administration of nAChR antagonists such
as the nonselective nAChR antagonist mecamylamine. Physical signs of nicotine withdrawal
assessed in rodents are hyperalgesia
grooming, and backing

89,94

85,93

, somatic signs, such as paw tremors, body tremors,

and alterations in locomotor activity 95. Cognitive signs induced by

nicotine withdrawal in rodents manifest as deficits in the number of reversals, increased
omissions, and reduced speed of responding in the probabilistic reversal learning task96.
Affective signs of nicotine withdrawal are anxiety-like behaviors as measured in the elevated
plus maze test and light-dark boxes
aversion (CPA) test
101,102

99,100

97,98

, dysphoric-related behaviors in the conditioned place

, and anhedonia as observed with elevated reward thresholds in ICSS

. Current smoking cessation therapies are thought to target the nicotine withdrawal

syndrome in humans and are effective in preclinical models of nicotine withdrawal attributing
predictive validity to these models. Varenicline and bupropion reduce cognitive deficits
bupropion attenuates somatic and affective signs

105,106

103,104

,

and nicotine replacement reverses

physical, affective, and cognitive signs 89,107 associated with the nicotine withdrawal syndrome in
rodents.

8

b. Nicotine Withdrawal Methods
In our lab, mice receive chronic nicotine via s.c. osmotic MPs that are implanted under
isoflurane anesthesia. Nicotine (24mg/kg/day) or saline is infused for 14 days and the
concentration of nicotine is adjusted according to animal weight and mini pump flow rate. On
the morning of day 15, mice are injected with vehicle or test drug before the challenge with the
nAChR antagonist, mecamylamine (2 mg/kg, s.c.). Withdrawal is assessed 10 min after
mecamylamine administration. Affective (anxiety-like behavior) and physical (somatic signs,
hyperalgesia) signs of nicotine withdrawal are evaluated in this paradigm. Anxiety-related
behavior is measure in the elevated plus maze test for 5 minutes. Time spent on the open arms of
the plus maze is assessed as a measure of anxiety-related response. The number of arm crosses
between the open and closed arms are counted as a measure of locomotor activity. Somatic signs
are assessed immediately following the plus maze test for 20 min. Somatic signs are measured as
paw and body tremors, head shakes, backing, jumps, curls, and ptosis. Mice are placed in clear
activity cages without bedding for the observation period. The total number of somatic signs is
tallied for each mouse and the average number of somatic signs during the observation period is
plotted for each test group. Hyperalgesia is evaluated using the hot plate test immediately
following the somatic sign observation period. Mice are placed into a 10-cm wide glass cylinder
on a hot plate (Thermojust Apparatus, Richmond, VA) maintained at 52°C. The latency to
reaction time (jumping or paw licking) is recorded. The specific testing sequence was chosen
based on our prior studies showing that this order of testing reduced within-group variability and
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produced the most consistent results 93. An observer blinded to experimental treatment performs
all studies.

D. Mechanisms Underlying Nicotine Reward
Nicotine initiates its rewarding effects by activating the natural reward system of the brain
known as the mesolimbic pathway. This pathway is comprised of dopaminergic neurons
originating in the ventral tegmental area (VTA) that project to regions such as the nucleus
accumbens (NAc), prefrontal cortex (PFC), amygdala and hippocampus

108–110

. Dopamine

release, especially in the NAc, is associated with the rewarding and reinforcing effects of all
drugs of abuse

111

.There have been many studies implicating this pathway in nicotine reward.

Blockade of dopamine receptors or 6-hydroxydopamine lesions in the mesolimbic pathway
results in a decrease in nicotine reward-like behavior in several preclinical tests such as selfadministration, CPP and ICSS

112,113

. Infusion of nicotinic antagonists directly in the VTA

attenuates nicotine self-administration114. Nicotine increases dopamine neuron firing rate and
dopamine release in areas of the brain such as the NAc shell, extended amygdala and PFC
108,112,115,116

via nAChRs

neurotransmitters

such

117

. This pathway has a complex circuitry that also involves other

as

glutamate,

γ-aminobutyric

acid

(GABA),

acetylcholine,

endocannabinoids, and opiod peptides. Glutamatergic, GABAergic, and cholinergic inputs
converge on dopamine neurons modulating dopamine release 118.
The excitatory neurotransmitter glutamate has been implicated in nicotine reward. Systemic
administration of glutamate ionotropic receptor antagonists attenuated nicotine-evoked increases
of dopamine levels in the NAc119. Behaviorally it has been shown that the glutamate N-methylD-aspartic acid (NMDA) receptor antagonist LY235959 infused into the VTA and the central
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nucleus of the amygdala (CeA) reduces the reinforcing effects of nicotine i.v. self-administration
and block nicotine ICSS facilitation in rats
increase glutamate release in the NAc

121,122

120

. Acute doses of nicotine have been shown to

. It has been suggested that dopamine release in the

NAc is dependent upon NMDA activation in the VTA123.
An enhancement of the inhibitory neurotransmitter GABA has been shown to reduce the
rewarding effects of nicotine. The GABAB receptor agonist, baclofen, attenuates nicotineinduced dopamine release in the NAc shell and reduces nicotine i.v. self-administration in rats
124,125

. In addition, the effect of baclofen in nicotine self-administration is dependent on GABAB

receptors in the VTA and the pedunculopontine tegmentum (PDT), an area in the brain stem
containing cholinergic and glutamatergic neurons

126,127

. Also, the GABAB receptor PAM

BHF177 reduces nicotine self-administration in rats after chronic exposure 128. This suggests that
modulation of the GABAB receptor is important in nicotine reward.
Cholinergic and glutamatergic neurons in the laterodorsal tegmentum (LDT) and the PDT
initiate excitation of dopamine neurons in VTA that project to the NAc

129,130

cholinergic neurons in the PDT reduce nicotine self-administration in rats

131

. Lesions of

. nAChRs are

located pre and postsynaptically throughout the mesolimbic circuitry 130,132,133. The utilization of
genetically mutant mice, pharmacological interventions, and viral re-expression approaches have
implicated particular brain areas and specific nicotinic subtypes involved in nicotine reward. The
nicotinic high-affinity β2-containing nAChRs are required for nicotine reward and reinforcement
as revealed in nicotine CPP and nicotine i.v. self-administration studies in β2 knockout (KO)
mice

37,134,135

. The β2 subunit co-assembles with the α6 and α4 subunits to form several α6β2*,

α4β2*,α4α6β2* nAChR subtypes, which have been notably expressed in the midbrain region
such as the VTA

136–138

. Nicotine CPP revealed a critical role of the α4, α6, and β2 subunits in
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the NAc via genetic mutant mice and site specific infusions139. In addition, a genetic ablation of
the β2, α6, and α4 nAChR subunits attenuated nicotine self-administration in mice but nicotine
self-administration was maintained in KO mice where the analogous subunit was only reexpressed in the VTA via a lentiviral vector

31,135

. Furthermore, in the nicotine CPP test α4

“knock-in” mice (Leu9’ Ala mutation renders animals hypersensitive to nicotine) produced a
preference for nicotine at a dose 50-fold lower than the typical nicotine dose that induces a
preference in wild type (WT) mice

140

. In recent years genome wide association studies in

humans revealed a variant in the CHRNB4/A3/A5 gene cluster (encodes α3, α5, β4 nicotinic
subunits), located in chromosome region 15q25, serves as a risk factor for lung cancer and
nicotine dependence141–143. More specifically, a reduction of function of CHRNA5 (D398N) is
linked to increased risk for tobacco dependence

144,145

. Indeed, in human pluripotent cells that

were induced into midbrain dopaminergic neurons, nAChRs that contained the nonsynonymous
human CHRNA5 D398N polymorphism (rs16969968) had a decreased potency of nicotine
compared to controls146and increased consumption of nicotine in intravenous self-administration
in mice147. Similarly, α5 KO mice have an increase in nicotine intake in the nicotine intravenous
self-administration test and do not display raised brain stimulated thresholds after administration
of an aversive dose of nicotine in comparison to their WT counterparts

147,148

. Similar

observations occurred in the nicotine CPP paradigm where α5 KO mice exhibited a maintained
nicotine preference at higher doses not maintained by α5 WT mice

149

. This suggests that the α5

subunit may act as an inhibitory responder that limits nicotine consumption and rewarding
effects

148,149

. α3β4* nAChRs mediate nicotine reward. The α3β4*-selective antagonist AuIB

attenuated nicotine preference in α5 WT and KO mice

150

suggesting the α3β4*nAChR

influences nicotine reward independent of the α5 subunit. In addition, β4 KO mice had a
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reduction in nicotine reinforcement and motivation to self-administer nicotine in the nicotine
intravenous self-administration paradigm 151. However, β4 subunit overexpression in Tabac mice
(transgenic mouse model of the Chrnb4-Chrna3-Chrna5 gene cluster) results in nicotine CPA
and a reduction in nicotine consumption

152

. The divergent effects of the β4 subunit in these

studies may be the result of different doses of nicotine used and the different aspects of nicotine
intake investigated (i.e. reward and aversion).
The nAChRs and cannabinoid (CB) receptors are both expressed in overlapping rewarding
brain regions and it has been shown that these two systems interact with each other

153,154

.

Genetic deletion of the CB1 receptor and administration of the CB1 receptor antagonist
rimonabant attenuates nicotine i.v. self-administration and nicotine CPP

155–157

. Conversely, a

synthetic CB1 receptor agonist WIN 55,212-2 enhances nicotine self-administration in rodents
158

. In addition, CB2 receptors play a role in nicotine reward. Nicotine CPP was abolished in CB2

KO mice and blocked after administration of the CB2 antagonist SR144528

159

. In addition,

pharmacological blockade or deletion of fatty acid amide hydrolase (FAAH), the degradative
enzyme for the endogenous CB receptor ligand anandamide (AEA), enhances nicotine reward as
seen in the nicotine CPP test 155. This suggests that indirect activation of CB receptors is capable
of enhancing nicotine reward.
The opioid system also plays a role in nicotine reward. The endogenous opioid system consists
of three receptors: mu (MOR), delta (DOR), and kappa (KOR) opioid receptors

160

. The

endogenous peptide β-endorphin binds the MOR with high affinity, met- and leu-enkephalin
bind to the DOR, and dynorphins preferentially bind to KORs 161. The MOR antagonist naloxone
attenuated nicotine intravenous self-administration

162

and nicotine CPP

163

. In addition, mice

lacking the endogenous MOR agonist β-endorphin and MOR KO mice both showed an
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attenuation of nicotine CPP 163,164. This suggests that the MOR may mediate nicotine reward and
reinforcement. Pharmacological blockade and genetic deletion of the DOR attenuates nicotine
CPP and self-administration as well

165

. In contrast, activation of KORs attenuate nicotine self-

administration 162, which supports its involvement in emotional states.

E. Mechanisms Underlying Nicotine Withdrawal
Reward systems in the brain undergo neuroadaptations after chronic exposure to nicotine in
tobacco products, which leads to nicotine dependence. Cessation from cigarette smoking induces
a withdrawal syndrome comprised of physical, affective and cognitive symptoms. The severity
of these symptoms is a risk factor for relapse

29,166

. Therefore, understanding the mechanisms

involved in nicotine withdrawal may aid in the production of more successful smoking cessation
therapies. Neuroadaptations caused by nicotine withdrawal involve neurotransmitter systems that
are also involved in nicotine reward: glutamate, GABA, dopamine, endocannabinoid, and opioid
systems 154,167.
There is evidence to suggest that glutamate plays a role in the affective and somatic signs
produced by nicotine withdrawal in rodents. It has also been shown that glutamate release and
NMDA activation is necessary for the manifestation of somatic signs in nicotine withdrawn mice
168

. Nicotine withdrawal-induced elevations of brain reward thresholds in ICSS are interpreted as

depression-like behavior

169

. Similar to nicotinic antagonists, antagonism of the α-Amino-3-

Hydroxy-5-Methyl-4-Isoxazole Propionic Acid (AMPA) glutamatergic receptor results in this
brain reward threshold elevation in nicotine-dependent rats170. Furthermore, activation of
glutamatergic autoreceptors produced elevation in reward thresholds170. This suggests that a
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reduction in glutamatergic transmission may possibly be responsible for the affective signs
induced by nicotine withdrawal. However, genetic deletion of the metabotropic glutamate
receptor 5 in mice attenuated the affective signs associated with nicotine withdrawal

101

. Taken

altogether, the glutamate system plays a role in the affective signs of withdrawal but different
glutamate receptor classifications may have divergent effects.
There is evidence to suggest that GABA neurotransmission plays a role in nicotine
withdrawal. Mice that lack the GABAB receptor exhibited attenuated somatic signs

171

. In

addition, GABAergic neurons in the interpeduncular nucleus (IPN) are activated during nicotine
withdrawal and attenuating the excitability of these neurons was shown to alleviate nicotine
withdrawal somatic signs in mice

168

. However, administration of GABAB receptor agonist,

PAM, and antagonist all elicited an exacerbation of depressive-like behavior as indicative of
elevated brain reward thresholds in ICSS 172. Further studies are needed to provide clarity for the
role of GABA in the affective signs induced by nicotine withdrawal.
Nicotine withdrawal is thought to produce a hypodopaminergic state evidenced by decreased
dopamine levels in the NAc of rats
brain reward deficits

169

173,174

, reduction in dopamine release in the NAc

175

, and

. KOR signaling may play a part in inducing this hypofunctional

dopaminergic state. KOR signaling has been associated with mood and depressive-like states
176,177

. KOR activation decreases dopamine levels in the NAc

178

by blocking dopamine release

and enhancing dopamine reuptake 179,180. This has sparked interest in its involvement in nicotine
withdrawal, especially the affective signs. Indeed, KOR antagonists nor-BNI, JDTic, and
LY2456302 alleviated the physical and affective signs of the nicotine withdrawal syndrome in
rodents 97,149,181.
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nAChRs are the predominate mediator of nicotine withdrawal symptoms. The nonselective
nAChR antagonist mecamylamine is known to precipitate nicotine withdrawal signs in nicotinedependent rodents

89,93,94,182

. Pharmacological interventions and mouse KO studies revealed that

nicotinic receptor subunits modulate different aspects of the nicotine withdrawal syndrome. The
differential expression and pharmacological profiles of nAChR subtypes may account for their
various involvement in nicotine withdrawal. The affective signs are primarily mediated by the β2
93,183

α6

184

β4

185

, and α7

185

as indicated in the elevated plus maze test, CPA and ICSS. The

physical signs of the nicotine withdrawal syndrome are mediated by α3150 α5
150,185

and a subset are mediated by α7 subunits

93,187

93,186

, α2

186

, β4

. One interesting feature of chronic nicotine

exposure is the upregulation of nAChRs, most notably α4β2*188. This phenomenon has been
observed in vitro

189

,in preclinical animal studies

190,191

and in humans

192

. Upregulation of

nAChRs after chronic administration may be in response to receptor desensitization to
compensate for receptors no longer responding to agonist activation; however, it is unknown
whether or not the upregulated receptors are functional

193

. Interestingly, rodent and human

studies suggest a positive correlation of nicotine withdrawal signs with upregulation of
α4β2*nAChRs 194,195.
Recently, neural circuitry such as the habenulo-interpeduncular pathway has been implicated
in nicotine withdrawal and aversion

148,186

. The habenula is subdivided into two regions: medial

habenula (MHb) and the lateral habenula (LHb)196. The MHb is predominately thought to play a
role in nicotine dependence and it has afferents that project to the IPN
expressed in the MHb-IPN pathway

198

197

. nAChRs are densely

. Indeed, microinjection of the nonselective nAChR

antagonist mecamylamine into the MHb or the IPN precipitated nicotine withdrawal in mice

186

.

In particular, blockade of the β4 subunit in the IPN induced nicotine withdrawal-induced somatic
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signs in mice168. In addition, infusion of the α6* nAChR-selective antagonist α-conotoxin MII in
the MHb attenuated anxiety-like behavior in nicotine withdrawn mice 199.
The endocannabinoid system has also been implicated in nicotine withdrawal. Activation of
CB1 receptors with delta 9-tetrahydrocannabinol (THC) has been shown to reduce the physical
signs of withdrawal in rodents

200

. FAAH KO mice and pharmacological inhibition of FAAH

results in an increase level of the endocannabinoid AEA

201

. AEA is an endogenous agonist at

the CB1 receptor; therefore, blockade of FAAH is thought to indirectly activate CB1 receptors.
Contrary to the effect of THC on nicotine withdrawal induced somatic signs, pharmacological
and genetic blockade of FAAH resulted in exacerbated somatic signs
ablation did not affect nicotine withdrawal-induced somatic signs

200

155

. Also, CB1 genetic

. The lack of effect on

nicotine withdrawal in CB1 KO mice could be the result of compensatory effects because the
CB1 receptor antagonist rimonabant attenuates somatic signs in nicotine withdrawn mice

155

addition, there is a report to suggest fluctuations in AEA levels in nicotine withdrawn rats

. In
202

.

Even though the levels of the endocannabinoid 2-arachidonylglycerol (2-AG) were unchanged in
nicotine withdrawn rats

202

, monoacylglycerol lipase (MAGL), enzyme responsible for the

degradation of 2-AG, KO mice exhibited attenuated nicotine withdrawal- induced somatic signs
and administration of the MAGL inhibitor, JZL184, reduced somatic and affective withdrawal
signs in a CB1-dependent manner 182. CB2 KO mice did not produce altered nicotine withdrawal
signs compared to their WT counterparts
had an attenuation of somatic signs

203

159

while another study suggested that CB2 KO mice

. The genetic backgrounds of the mice used in the studies

were different and may account for the divergent effect observed in nicotine withdrawal. Taken
together, more investigation is warranted to understand the role of the endocannabinoid system
in nicotine withdrawal.
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F. α7 nAChR Physiological and Pharmacological Properties
Many potential targets and neurotransmitter systems involved in the various aspects of
nicotine dependence have been discussed above. These neurotransmitter systems are important,
but nAChRs are the primary targets of nicotine. Thus, this dissertation will primarily focus on
the nAChRs of the cholinergic system. There are two abundant nicotinic subtypes found in the
brain, β2* and α7 nAChRs49. However, the role of the α7 nAChR is understudied in nicotine
dependence in comparison to β2* nAChRs. β2* nAChRs have been the primary focus of nicotine
dependence research. It has been shown that low nicotine levels that smokers are exposed to
occupy the majority of high affinity β2* nAChRs in the brain
upregulated in postmortem brains of smokers

206

204,205

and animals

. These receptors are also

207

who received nicotine

chronically. In addition, preclinical studies showed that the β2 subunit is required for nicotine
reward, reinforcement, and some aspects of withdrawal 93,134,135,183. However, given the ability of
the β2 subunit to co-assemble with multiple subunits forming various nicotinic receptor subtypes
with different pharmacological and expression profiles, it has become arduous to identify which
β2* nAChR subtypes are involved in nicotine dependence. In addition, β2-targeting smoking
cessation aids such as varenicline and nicotine replacement therapies have modest efficacy.
Thus, it is important to investigate other molecular targets. The other most abundant nicotinic
receptor found in the brain, α7 nAChR, is found in areas related to reward such as the
hippocampus, amygdala, VTA, NAc, and IPN

41,122,208

. In addition, the α7 nAChR has unique

characteristics that set it apart from other nAChR subtypes. The structure of the α7 nAChR
shares a high homology with the acetylcholine binding protein (AChBP) found in snails 209. The
α7 nAChR is made up of five identical α7 subunits creating five potential binding sites between
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the interfaces in contrast to the heteromeric (α4)2(β2)3 nAChRs with only two binding sites
210,211

. There has been evidence to suggest that the α7 subunits can co-assemble with β2 subunits

forming a heteromeric receptor with the following combinations: (α7)3(β2)2 and (α7)4(β2)1
215

212–

. However, the implications and function of this receptor subtype in the mammalian brain is

not well understood. All nAChRs are permeable to cations such as Na+ and Ca2+; however, α7
nAChRs favor Ca2+ influx over Na+ in a ratio of 10:1 216,217 which is a critical feature for its role
in neurotransmitter release. α7 nAChRs located on presynaptic mesolimbic neurons function as
modulators of neurotransmitter release
glutamatergic terminals in the VTA

218

48

. Activation of presynaptic α7 nAChRs on

, modulate glutamate release that activates dopaminergic

neurons and causes dopamine release in the NAc

218,219

. In addition, α7 nAChRs are found on

glutamatergic terminals in the VTA that synapse to GABAergic neurons

220

that upon activation

inhibit dopamine neurons. In the NAc, α7 nAChRs on glutamatergic afferents that synapse to
medium spiny neurons can potentiate glutamate release and concomitantly activate ionotropic
glutamate receptors on dopaminergic axon terminals

221,222

inducing dopamine release.

Furthermore, preterminal α7 nAChRs on glutamatergic terminals in the NAc can also induce
metabotropic glutamate receptor activation on dopaminergic terminals, resulting in an
attenuation of dopamine release 223. A depiction of the neurocircuitry of α7 nAChRs in the VTA
and NAc can be found in Fig.1. In the PFC preterminal α7 nAChRs on glutamatergic terminals
induce dopamine release in this brain region via involvement of ionotropic glutamate receptors
on dopaminergic terminals

224,225

. α7 nAChRs are also located post and extrasynaptically in

brain areas such as the hippocampus, VTA and PFC where they are thought to aid in traditional
fast synaptic transmission

218,226–228

. Postsynaptic α7 nAChRs in the CA1 region of the

hippocampus are involved in the induction of long term potentiation
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229

In contrast to β2*

nAChRs, α7 nAChRs have a low probability of being open and are profoundly desensitized in
the presence of high agonist concentrations

230

. The desensitization of the α7 nAChRs alters it

function throughout the neurocircuitry and may lead to different net outcomes on
neurotransmitter release.
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Figure 1: Schematic of α7 nAChR Neurocircuitry in the VTA and NAc (Adapted from 231)
A: (1) α7 nAChRs located on glutamatergic terminals synapse onto dopaminergic neurons in the
VTA. (2) Somatodendritic α7 nAChRs are located on dopamine neurons in the VTA. (3)
Preterminal α7 nAChRs on glutamatergic afferents synapse with medium spiny neurons and
glutamate release stimulates ionotropic glutamate receptors on dopaminergic neurons in the
NAc. B: (4) Glutamatergic terminals in the VTA possess α7 nAChRs. The glutamatergic
afferents synapse onto GABAergic neurons and they inhibit dopamine neurons. (5) In the NAc,
presynaptic α7 nAChRs are located on glutamatergic terminals. They synapse onto medium
spiny neurons and glutamate release activates metabotropic glutamate receptors on dopaminergic
terminals.
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G. Conformational Regulation of α7 nAChRs by Pharmacological Interventions
The conformational changes of the α7 nAChR may play an important role in its
pharmacological and molecular effects in different disease states. The α7 nAChR is an allosteric
protein with orthosteric (traditional) binding sites and allosteric binding sites. Activation of the
α7 nAChR which an orthosteric agonist is known to produce intrinsically limiting factors such as
a low probability of opening and a rapid desensitization rate

51

. To circumvent these limitations

and/or understand the effects of desensitization and enhanced channel opening in different
behavioral responses, several types of allosteric modulators of α7 nAChRs were developed. For
example, PAMs bind to allosteric sites most likely in the transmembrane domain of the receptors
232,233

and increase the effectiveness of an orthosteric agonist. The presence of an orthosteric

agonist is required for activation to occur. In comparison to orthosteric agonists, PAMs modulate
the endogenous tone and restrict activation to only where acetylcholine is released and choline is
present 234. PAMs are broadly classified into two groups: Type I PAMs and Type II PAMs. Type
I PAMs, such as NS1738, increase the probability of opening of α7 nAChRs by attenuating the
energy barriers that prevent transitions to the active state of the receptor. In contrast, Type II
PAMs, such as PNU120596, not only increase the opening probability, but alter the equilibrium
of the receptor in such a way that the active state is favored over the desensitized state resulting
in prolonged opening

235,236

. Both PAMs increase the probability of channel opening and thus

increase channel conductance; however, this is a sole feature attributed to Type 1 PAMs.
Therefore, Type I PAMs can serve as pharmacological tools to investigate the effect of enhanced
channel conductance of the α7 nAChRs. Type II PAMs not only increase the probability of
opening but also reduce the desensitization rate. They can also reactivate receptors that are
desensitized

42

. These pharmacological tools can be used to identify the role of α7 nAChR
22

desensitization rate especially if both categories of PAMs are used in the same studies along with
an orthosteric agonist. PAMs could also provide more selectivity for α7 nAChR activation since
α7 nAChRs and serotonin 5-HT3 receptors have a high homology of their ligand binding
domains
238,239

237

. Both categories of PAMs were shown to have potential procognitive properties

, and anti-inflammatory and anti-allodynic effects in rodents 240,241.

Ligands known as dual allosteric agonist-PAMs (Ago-PAMs) were reported in vitro to have
both agonist and PAM properties 242. The Ago-PAM GAT107 is the active isomer of the Type II
α7 nAChR PAM TQS and is thought to bind to the same site as PNU120596 to induce its
allosteric modulation effects. GAT107 does not bind to the orthosteric site to induce its direct
receptor activation but another distinct allosteric site. The orthosteric site does not need to be
occupied for GAT107 to induce its effect

243

. The Ago-PAMs may be used to understand α7

nAChR activation independent of the orthosteric site. GAT107 has been shown to reduce
inflammatory and neuropathic pain in rodents 244.
The recent emergence of silent agonists for the α7 nAChR, such as NS6740, represents an
interesting and new approach to modulate α7 nAChR subtypes. α7 nAChR silent agonists are
high affinity ligands that bind to the orthosteric binding site but possess very low efficacy (<23%) 245. They are considered “desensitizers” that bind to α7 nAChRs and induce conformational
changes that favor the desensitization state over the active state 246. The agonist properties of the
silent agonist are revealed once co-applied with a type II PAM

44

suggesting that it acts as a

typical agonist after the destabilization of desensitization. α7 nAChR silent agonists can serve as
pharmacological tools to assess the effect of α7 nAChR desensitization/ lack of conductance in
disease states. For example, while NS6740 was ineffective in rodent cognition assays
shown analgesic-like properties in chronic pain models

23

246

245

, it has

, suggesting that there may be a

necessity of ion conductance/ desensitization of the α7 nAChR for CNS-related behavioral
effects.
The pharmacological effect of these new α7 nAChR ligands is unknown in preclinical
nicotine dependence models. The utilization of these ligands could implicate distinct
conformations of the α7 nAChR that are necessary for certain aspects of nicotine dependence.
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Figure 2: Schematic of proposed α7 nAChR binding sites and conformations (Adapted from
243,247
)
A. PAMs such as NS1738 and PNU120596 are thought to bind to the PAM site (P). Ago-PAMs
such as GAT107, are thought to bind two separate sites on the receptor: a PAM site (P) and a
unique site for direct allosteric activation (DAA) (D). Silent Agonists (NS6740) and traditional
agonists (acetylcholine or nicotine) bind to the orthosteric site (A).B. nAChRs have three general
conformation states: the closed state (C), the open state (O), and the desensitized state (D). Silent
agonists induce conformational changes that favor the desensitized state over the active state.
Silent agonists bind to the receptor yet do not produce ion conductance of the receptor like
typical orthosteric agonists.
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Table 1: α7 nAChR Modulators

Name

Type of α7
nAChR
Modulator

PNU282987

Orthosteric full
agonist

Structure, Efficacy/Potency

Selectivity for
alpha 7 nAChR

> 400 times more
selective for α7
than α3β4
> 100 times more
selective for α7
than α4β2 nAChR

Affinity:
Ki: 27nM
248

248

EC50 154nM 248

NS1738

~ 8- and 26-fold
selectivity for
potentiation of α7
versus inhibition
of α3β4 and α4β2
nAChRs
respectively.

Type I PAM

Affinity: N/A

232,249

~2-3 fold increase in the maximal efficacy of
ACh 232,249
PNU120596

no change in
current in α4β2,
α9α10 , and α3β4
nAChRs

Type II PAM

Affinity: N/A

250

~3fold increase in the maximal efficacy of ACh
250,251

NS6740

> 1000 times more
selective for α7
than α4β2 nAChR

Silent Agonist

Affinity
Ki:1.1 nM

245

245

NS6740 efficacy: <3% of the response to ACh
at both human and rat α7 nAChR245
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H. α7 nAChR Involvement in Nicotine Dependence
The α7 nAChR plays an important role in inflammation and cognition. However, there is recent
evidence implicating α7 nAChRs in nicotine dependence. Polymorphisms of the CHRNA7 gene
(encodes for α7 nAChR) have been linked to nicotine dependence in various human studies
254

252–

. Initially, in preclinical studies null mutant mice and pharmacological studies revealed that α7

nAChRs were not necessary for nicotine reward

31,37,255

and did not play a significant role in

nicotine withdrawal93. In nicotine CPP, a dose of nicotine (0.5mg/kg) known to produce a
significant preference78,80 was unaltered in α7 KO mice

37

. However, it was recently observed

that α7 KO mice have nicotine preferences for lower doses of nicotine that do not induce a
preference in their WT counterparts

35

. This observation suggested that genetic deletion of α7

nAChRs increases sensitivity to nicotine in the CPP test. Similar findings were reported with
nicotine reinforcing properties. Nicotine intravenous self-administration studies either observed
dose-related reduction

90,256

or no effect255 by systemic administration of the relatively selective

α7 nAChR antagonist methyllycaconitine (MLA). In contrast, selective pharmacological
blockade of α7 nAChRs by the α-conotoxin ArIB in the NAc shell enhanced nicotine intake in
the intravenous self-administration procedure 30. ArIB is more than 500 times more selective for
α7 nAChRs than other nAChR subtypes

257

. MLA has been shown to have off-target effects at

α6*, α3*, β3* nAChRs at similar doses used to block α7 nAChRs258. In fact, MLA has been
shown to precipitate nicotine withdrawal signs in α7 KO mice 94. Thus, non-α7 nAChRs may be
responsible for the effects of MLA in these studies and ArIB may be a more selective antagonist
to probe the effect of pharmacological blockade of α7 nAChRs in nicotine reward. Similarly, the
use of MLA in ICSS yielded equivocal results with reports suggesting that MLA had no effect on

27

nicotine-induced ICSS facilitation90 or attenuated nicotine facilitation259. In the drug
discrimination paradigm MLA

260

and α7 nAChR genetic deletion

261

did not alter the

discriminative stimulus effect of nicotine suggesting that the α7 nAChR is not involved in this
effect. Until recently, the effect of α7 nAChR activation in nicotine reward was unknown. α7
nAChR orthosteric agonists, such as PHA543613 and PNU282987, attenuated nicotine reward in
the CPP test

35

, and nicotine reinforcement in intravenous nicotine self-administration

30

.

Similarly, α7 knock-in mice (mice heterozygous for a Leu250-to-Thr substitution in the channel
domain of α7 subunit, which creates a gain-of-function mutation) had abolished nicotine
preference

35

. Taken together, these studies suggest that activation of α7 nAChRs reduce the

rewarding and reinforcing properties of nicotine in rodents. Interestingly, as mentioned
previously, activation of α7 nAChRs and β2* nAChRs, which are required for nicotine reward
114,135

. induce dopamine release

123,136,262,263

but have divergent effects behaviorally in nicotine

reward paradigms. β2* nAChR agonists substitute for nicotine in self-administration
discrimination

265

and facilitate ICSS

nicotine in drug discrimination

265

266

264

drug

. In contrast, α7 nAChR agonists do not substitute for

facilitate ICSS

266

or induce self-administration

30

.

Collectively, this suggests that α7 nAChRs may play a modulatory role on nicotine reward in
comparison to β2* nAChRs. There is a need to understand signaling pathways involved in this
effect.
There is limited literature implicating α7 nAChRs in the nicotine withdrawal syndrome.
Nicotine withdrawn α7 KO mice exhibit an attenuation of hyperalgesia

93,187

. There have been

reports suggesting that α7 KO mice do not exhibit altered somatic signs compared to their WT
counterparts93,185,187; however, one study observed a reduction in somatic signs in α7 KO mice 94.
The latter study may differ from the previous reports due to the different somatic signs that were
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recorded. The α7 nAChR antagonist MLA precipitates a subset of nicotine withdrawal somatic
signs 89,94,95 while in another study MLA had no effect 90. This may be due to species difference.
The studies that observed precipitation of somatic signs by MLA used mice while MLA had no
effect in rats. α7 KO mice withdrawn from nicotine had an attenuation of anhedonia as measured
by ICSS

185

, but anxiety-like behavior and CPA is unaffected in α7 KO mice

93

. This suggests

that different mechanisms may underlie these affective nicotine withdrawal signs. A recent study
investigated the effect of α7 nAChR activation in nicotine withdrawal. The α7 full agonist ABT107 attenuated nicotine withdrawal-induced anxiety as measured in the novelty-induced
hypophagia (NIH) test

267

. There is a need of further investigation of α7 nAChR activation in

nicotine withdrawal.

I. Possible Mechanisms of α7 nAChRs in Nicotine Dependence
The high Ca 2+ permeability of the α7 nAChR results in increases of intracellular Ca 2+, causing
the opening of other channels such as voltage dependent Ca

2+

channels227, consequently

resulting in neurotransmitter release. α7 nAChR activation can also activate Ca2+-dependent
signaling pathways. In preclinical cognitive studies, α7 nAChRs enhance cognition by activating
extracellular receptor kinase (ERK) /mitogen-activated protein kinase (MAPK) and cyclic AMP
response element-binding protein (CREB) signaling in a Ca2+-dependent manner

268–270

α7

nAChR activators are undergoing clinical trials to treat cognitive disorders 271.
In addition, evidence suggests that the α7 nAChRs bind guanosine triphosphate-binding
proteins (G proteins) to induce a Ca2+-mediated or channel independent signaling cascades
involved in dendrite plasticity

272,273

. In support of the metabotropic nature of the α7 nAChRs,

the α7 nAChR silent agonist NS6740 displayed analgesic-like properties in a neuropathic pain

29

model246. Silent agonists render the receptor in a nonconductive state, thus it is plausible that the
analgesic effects of the α7 nAChRs are modulated through metabotropic signaling. Indeed, α7
nAChRs on non-conducting cells such as macrophages are required for acetylcholine induced
inhibition of pro-inflammatory cytokine production

274

. In addition, evidence suggests that α7

nAChRs modulate Ca2+-independent signaling pathways such as the Janus kinase 2
(JAK2)/signal transducer and activator of transcription (STAT) in immune cells which may have
implications in inflammation

275

. Also recently, genomic analysis has suggested that the Chrna7

gene in mice (encodes for the α7 nAChR) regulates an insulin gene expression network in the
NAc35. Future pharmacological and genetic investigations may clarify this possible interaction.
The previously mentioned signaling cascades provide evidence that α7 nAChRs not only act as
ionotropic receptors, but metabotropic properties as well.
Recently, PPARα has been shown to modulate the rewarding properties of nicotine

115

.

PPARα is a transcription factor classically involved in inflammation and lipolysis 276. Activation
of PPARα reduces nicotine reward and reinforcement

34,154,277

. It has been hypothesized that α7

nAChR activation might indirectly lead to downregulation of β2* nAChRs via PPARα-induced
phosphorylation of these subunits 116,278. Since β2* nAChRs are required for nicotine reward and
reinforcement

37,135

, this pathway could provide an explanation of the effects of α7 nAChR

activation in nicotine reward studies. Indeed, it has been shown that α7 nAChRs may fine-tune
nicotine-induced DA neuron firing only after β2* nAChRs have been activated 279. This suggests
that α7 nAChRs may indirectly regulate β2* nAChRs function. Therefore, it is imperative to
investigate this possible signaling pathway in nicotine dependence. Fig. 3 displays a proposed
model implicating PPARα as a possible downstream mediator of α7 nAChRs activation in
nicotine reward.

30

Figure 3: Schematic diagram of the proposed mechanism of PPARα and α7 nAChR
interaction in nicotine reward (Adapted from 116)
Activation of α7 nAChRs induced by an exogenous agonist such as PNU282987 induces Ca2+
influx. This stimulates the synthesis of the endogenous PPARα agonists, oleoylethanolamide
(OEA) and palmitoylethanolamide (PEA). These molecules then activate PPARα, which may
reduce nicotine dependence. PPARα can be activated with exogenous agonists such as WY14643 and the clinically used drug to treat high cholesterol, fenofibrate. PPARα can be blocked
with antagonists such as MK886 and GW6471. This mechanism will be investigated using the
mentioned pharmacological ligands in chapter 3.
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J. Dissertation Aims
We hypothesize that the role of the α7 nAChR in nicotine dependence requires ion conductance
and is PPARα mediated. To test this hypothesis this dissertation: 1) investigated the impact of
pharmacological modulation of α7 nAChR in mouse models of nicotine dependence and 2)
evaluated a possible role for PPARα as a downstream mediator of α7 nAChR in nicotine
dependence. The effect of the α7 nAChR Type I PAM NS1738, Type II PAM PNU120596, and
silent agonist NS6740 are unknown in nicotine reward and withdrawal assays. The utilization of
these pharmacological tools will aid in the understanding of probability of channel opening
(NS1738, PNU120596), desensitization (PNU120596, NS6740), and modulation of the
endogenous acetylcholine/ choline tone (NS1738, PNU120596) as it relates to the α7 nAChR in
nicotine dependence studies. In addition, it is unknown whether an α7 nAChR and PPARα
interaction exists in nicotine dependence. There is evidence to suggest that α7 nAChR activation
attenuates nicotine reward; however, the mechanism is not well understood. Recently the nuclear
receptor PPARα has been shown to attenuate nicotine reward and reinforcement. Futhermore, a
study indicated that α7 nAChRs may indirectly activate PPARαs. This interaction has not been
investigated in nicotine reward and PPARα activation has not been studied in nicotine
withdrawal thus this dissertation seeks to elucidate the role of α7 nAChR and PPARα in nicotine
dependence using pharmacological interventions.
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CHAPTER TWO

Modulation of the α7 Nicotinic Acetylcholine Receptor in Nicotine Dependence

A. Introduction

Even though there are many well-known health risks associated with tobacco use, tobacco
dependence remains one of the leading sources of preventable death worldwide
current pharmacological interventions available have modest efficacy

26

204,280

. The

; therefore, there is a

need for a better understanding of the neural substrates involved in nicotine dependence to
design and develop more effective smoking cessation aids. Nicotine dependence can be divided
into two parts: nicotine reward and nicotine withdrawal. Both of these aspects of nicotine
dependence have been investigated and the main molecular targets that have been studied are
nAChRs. nAChRs are the primary target of nicotine, the addictive component in tobacco
products. These receptors exist in multiple subtypes; however, the most predominate nAChRs in
homomeric α7 and heteromeric α4β2* (where *denotes the

the mammalian brain are the

possible inclusion of additional nAChR subunits) respectively

49

. Even though activation of α7

nAChRs has been shown to induce dopamine release in the mesolimbic pathway

262,281

behavioral studies suggested little involvement of the α7 nAChR in nicotine reward

, early
255,260

.

However, recently it has been shown that ArIB, a selective α7 nAChR antagonist, infused in the
NAc shell increased nicotine intake in nicotine intravenous self-administration procedure

30

.

Similarly, the genetic deletion of α7 nAChR in mice enhanced nicotine reward as measured in
the CPP test

35

.

In contrast, α7 knock-in mice (mice heterozygous for a Leu250-to-Thr

substitution in the channel domain of α7 subunit, which creates a gain-of-function mutation) had
abolished nicotine preference

35

. Furthermore, PNU282987, an α7 nAChR agonist, infused
33

locally into the NAc shell was found to reduce nicotine intake in intravenous self-administration
in rats. This suggests that the α7 nAChR may play a modulatory role in nicotine dependence that
is in contrast to β2* nAChRs, which are required for nicotine reward

37,135

(please see Ch.1

Section H for more details).
The role of the α7 nAChR in nicotine withdrawal has not been studied extensively. Nicotine
withdrawal, the primary negative reinforcer that strengthens nicotine dependence, is one of the
primary causes of high tobacco relapse rates

29

. In humans, it consists of somatic signs such as

bradycardia, as well as non-somatic signs such as anxiety and depression 282. The physical signs
of nicotine withdrawal in rodents is measured by the observation of somatic signs, hyperalgesia
and affective signs such as anxiety-like behaviors

89,283

. Few studies have been performed

utilizing null mutant α7 mice in nicotine withdrawal. α7 knockout mice rendered dependent on
nicotine showed a reduction in hyperalgesia

93,187

,no alterations in their somatic signs

attenuated anxiety-like behavior compared to their wild type counterparts

185

93,187

and

. Pharmacological

blockade of the α7 receptor with MLA has been shown in some studies to precipitate a subset of
nicotine withdrawal somatic signs in rats and mice
ineffective at inducing nicotine withdrawal signs

90

89,94,95

while in other studies MLA was

. Recently, the α7 nAChR agonist ABT-107

was shown to reduce nicotine withdrawal-induced anxiety-like behaviors in mice 267.
There is a need for further investigation of the role of α7 nAChRs in nicotine dependence.
The homomeric α7 nAChR has unique features of high calcium permeability, rapid
desensitization and low probability of channel opening

42,50

. The recent development of α7

nAChR modulators such as PAMs and silent agonists may aid in understanding these
characteristics in nicotine dependence paradigms. A Type I PAM such as NS1738 enhances the
channel opening probability of α7 nAChRs while the Type II PAM, PNU120596 not only

34

increases the opening probability, but slows the desensitization rate of the receptor which results
in prolonged channel opening235,236. The α7 nAChR silent agonist NS6740 is an orthosteric
ligand that desensitizes the receptor by inducing conformational changes that favor the
desensitization state over the active state

246

(please see Ch. 1 Section G for more details). To

date, the impact of these α7 nAChR modulators in nicotine dependence paradigms are unknown.
Therefore, the current study investigated the physiological properties of the α7 nAChR in the
nicotine CPP and nicotine withdrawal tests. The Type I PAM NS1738 and Type II PAM
PNU120596 were used to evaluate the effect of channel opening probability and modulation of
endogenous acetylcholine/ choline tone. The Type II PAM PNU120596 and silent agonist
NS6740 were used to evaluate the role of desensitization and channel opening in nicotine
dependence. The orthosteric full agonist PNU282987 was used as a reference compound. The
findings of this study will advance the understanding of the α7 nAChR in nicotine dependence.

B. Materials and Methods
Animals
Drug-naive, ICR male mice (8 weeks old upon arrival; Harlan Laboratories, Indianapolis, IN)
served as subjects. Mice were housed four per cage with ad libitum access to food and water on a
12-h light cycle in a humidity and temperature controlled vivarium that was approved by the
Association for Assessment and Accreditation of Laboratory Animal Care. Mice received corn
cob bedding and were fed Envigo Teklad mouse/rat diet 7102 (LM-485). Experiments were
performed during the light cycle and were approved by the Institutional Animal Care and Use
Committee of Virginia Commonwealth University and followed the National Institutes of Health
Guidelines for the Care and Use of Laboratory Animals.
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Drugs
(−)-Nicotine hydrogen tartrate [(−)-1-methyl-2-(3- pyridyl) pyrrolidine (+)-bitartrate] and
mecamylamine HCl (non-selective nAChR antagonist) were purchased from Sigma-Aldrich Inc.
(St. Louis, MO, USA). PNU120596 [1-(5-Chloro-2, 4-dimethoxy-phenyl)-3-(5-methyl-isoxazol3-yl)] and PNU282987 [N-(3R)-1 Azabicyclo [2.2.2] oct-3-yl-4-chlorobenzamide] were obtained
from the National Institute on Drug Abuse (NIDA) supply program (Bethesda, MD). NS6740
(1,4-diazabicyclo[3.2.2]nonan-4-yl(5-(3-(trifluoromethyl) phenyl) furan-2-yl) methanone) was
prepared as previously described (Peters et al., 2004). NS1738 was purchased from Tocris
Biosciences (Minneapolis, MN). Nicotine, NS6740, mecamylamine,and PNU282987 were
dissolved in physiological saline. NS1738 and PNU120596 were dissolved in a mixture of 1:1:18
[1 volume ethanol/1 volume Emulphor-620 (Rhone-Poulenc, Inc., Princeton, NJ) and 18
volumes distilled water]. Nicotine and PNU282987 were injected s.c. while all other drugs were
administered intraperitoneally (i.p.). The nicotine solution pH was neutralized with sodium
bicarbonate as needed. Freshly prepared solutions were given to mice at 10 ml/kg, s.c. Doses are
expressed as the free base of the drug.

Nicotine conditioned place preference studies
An unbiased CPP paradigm was performed, as we previously described 284. Briefly, the CPP
apparatus consisted of three chambers in a linear arrangement (Med Associates, St Albans, VT).
The CPP apparatus (MedAssociates, St. Albans, VT, ENV3013) consisted of white and black
chambers (20×20×20 cm each), which differed in overall color and floor texture (white mesh or
black rod). These chambers were separated by a smaller gray chamber with a smooth PVC floor.
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Partitions could be removed to allow access from the gray chamber to the black and white
chambers. On day 1, animals were confined to the middle chamber for a 5-min habituation and
then allowed to freely move between all three chambers for 15 min. Time spent in each chamber
was recorded, and these data were used to populate groups of approximately equal bias in
baseline chamber preference. Twenty-minute conditioning sessions occurred twice a day (days
2–4). During conditioning sessions, mice were confined to one of the larger chambers. The saline
groups received saline in one large chamber in the morning and saline in the other large chamber
in the afternoon. The nicotine group received nicotine in one large chamber and saline in the
other large chamber. Treatments were counterbalanced equally in order to ensure that some mice
received the unconditioned stimulus in the morning while others received it in the afternoon. The
nicotine-paired chamber was randomized among all groups. Sessions were 4 hrs apart and were
conducted by the same investigator. On each of the conditioning days, mice were pretreated with
PNU282987 (s.c.), NS1738 (i.p.) PNU120596 (i.p.), NS6740 (i.p.) or their respective vehicle 15
min prior to nicotine injection. On test day (day 5), mice were allowed access to all chambers for
15 min in a drug free state. The preference score was calculated by determining the difference
between the time spent in the drug paired side during test day versus the time in drug paired side
during the baseline day.

Nicotine Precipitated Withdrawal Studies
Mice were infused with 24 mg/kg/day nicotine or saline for 14 days using s.c. osmotic MPs
(model 2000; Alzet Corporation, Cupertino, CA) that were implanted under isoflurane
anesthesia. The concentration of nicotine was adjusted according to animal weight and mini
pump flow rate. On the morning of day 15, mice were injected with vehicle, PNU120596 (3,
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9 mg/kg, i.p.), PNU282987 (1, 3, 9 mg/kg, s.c.) or NS1738 (1,10 mg/kg, i.p.) 15 min before the
challenge with the nonselective nAChR antagonist, mecamylamine (2 mg/kg, s.c.), that was
administered 5 min after vehicle or drugs. Withdrawal assessment was performed 10 min later as
described in

93

. Affective (anxiety-like behavior) and physical (somatic signs, hyperalgesia)

nicotine withdrawal signs were evaluated in this paradigm. Mice were first evaluated for 5 min in
the plus maze test for anxiety-related behavior. Time spent on the open arms of the plus maze
was assessed as a measure of anxiety-related response. The number of arm crosses between the
open and closed arms was also counted as a measure of locomotor activity. The plus maze
assessment was immediately followed by a 20-min observation of somatic signs measured as
paw and body tremors, head shakes, backing, jumps, curls, and ptosis. Mice were placed in clear
activity cages without bedding for the observation period. The total number of somatic signs was
tallied for each mouse and the average number of somatic signs during the observation period
was plotted for each test group. Hyperalgesia was evaluated using the hot plate test immediately
following the somatic sign observation period. Mice were placed into a 10-cm wide glass
cylinder on a hot plate (Thermojust Apparatus, Richmond, VA) maintained at 52°C. The latency
to reaction time (jumping or paw licking) was recorded. The specific testing sequence was
chosen based on our prior studies showing that this order of testing reduced within-group
variability and produced the most consistent results

93

. All studies were performed by an

observer blinded to experimental treatment.

Statistical analysis
Data were analyzed using the GraphPad software version 6.0 (GraphPad Software, Inc., La Jolla,
CA) and expressed as the mean ± S.E.M. A one-way analysis of variance (ANOVA) in
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conjunction with Holm-Šídák comparison tests were conducted to determine significant effects
of drug treatments vs controls. Comparisons were considered statistically significant when p <
0.05.

C. Results
Nicotine CPP attenuated by α7 nAChR full orthosteric agonist PNU282987
Mice were conditioned with either saline or nicotine (0.5 mg/kg) for 3 days in the CPP paradigm.
A robust CPP was observed in nicotine – conditioned mice pre-treated with vehicle [F (4, 29) =
14.05, p<0.0001]. PNU282987 reduced nicotine reward. Post hoc analysis revealed that
pretreatment with a lower dose of PNU282987 (1 mg/kg) did not significantly alter nicotine CPP
(p>0.05), but a higher dose of the agonist (9mg/kg) did (p<0.05) (Fig. 4). PNU282987 at the dose
of 9 mg/kg did not produce a preference or aversion in saline treated-mice. PNU282987 was
administered within the range of doses used for other behavior studies 265,285.
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Figure 4: α7 nAChR Full Orthosteric Agonist PNU282987 Blocks Nicotine CPP
Mice underwent 3 days of conditioning with s.c. saline or nicotine (0.5mg/kg). Nicotine
produced a robust CPP in mice pre-treated with vehicle. The α7 full orthosteric agonist
PNU282987 (1 and 9 mg/kg; s.c.) attenuated nicotine reward as measured by the CPP. * Denotes
p<0.05 from vehicle-vehicle. # Denotes p<0.05 from nicotine control. Each point represents the
mean ± SEM of n=9-10 mice per group.
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α7 nAChR Type I PAM NS1738 had no effect on Nicotine CPP
CPP conditioning with either saline or nicotine (0.5 mg/kg) was performed for 3 days. CPP was
observed in nicotine–conditioned mice pre-treated with vehicle [F (4, 32) = 6.434, p =0.0006]
NS1738 did not reduce nicotine reward at either dose tested (1 and 10mg/kg) (p>0.05) (Fig. 5).
NS1738 at the dose of 10 mg/kg did not produce a preference or aversion in saline treated-mice.
NS1738 was used at doses previously described 240,286.
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Figure 5: α7 nAChR Type I PAM NS1738 Did Not Block Nicotine CPP
Mice underwent 3 days of conditioning with either s.c. saline or nicotine (0.5mg/kg). Nicotine
produced a robust CPP in mice pre-treated with vehicle. The α7 Type I PAM NS1738 (1 and 10
mg/kg; i.p.) did not alter nicotine reward as measured by the CPP test at both doses tested. *
Denotes p<0.05 from vehicle-vehicle. Each point represents the mean ± SEM of n=6-9 mice per
group.
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α7 nAChR Type II PAM PNU120596 reduced Nicotine CPP
CPP conditioning with either saline or nicotine (0.5 mg/kg) was performed for 3 days. CPP was
observed in nicotine–conditioned mice pre-treated with vehicle reward [F (4, 42) = 7.864, p <
0.0001]. PNU120596 significantly reduced nicotine reward. PNU120596 attenuated nicotine
CPP at both doses tested (1 and 9 mg/kg) (p<0.05) (Fig. 6). PNU120596 at the dose of 9 mg/kg
did not produce a preference or aversion in saline treated-mice. PNU120596 was used at similar
doses previously described 240,241.
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Figure 6: Attenuation of the Development of Nicotine CPP by α7 nAChR Type II PAM
PNU120596.
Mice underwent 3 days of conditioning with either saline or nicotine (0.5mg/kg;s.c.). Nicotine
produced a significant CPP in mice pre-treated with vehicle. The α7 Type II PAM PNU120596
(1 and 9 mg/kg; i.p.) reduced nicotine reward as measured by the CPP test at both doses tested. *
Denotes p<0.05 from vehicle-vehicle. # denotes p<0.05 from nicotine control. Each point
represents the mean ± SEM of n=9-10 mice per group.
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α7 nAChR Silent Agonist NS6740 Did Not Attenuate Nicotine CPP
CPP conditioning with either saline or nicotine (0.5 mg/kg) was performed for 3 days. CPP was
observed in nicotine – conditioned mice pre-treated with vehicle [F (4, 36) = 6.186 p=0.0007].
NS6740 had no effect on nicotine reward at both doses tested (1 and 3 mg/kg) (Fig. 7). NS6740
at the dose of 3 mg/kg did not produce a preference or aversion in saline treated-mice. NS6740
was used at doses previously described 246.
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Figure 7: No Effect of α7 nAChR Silent Agonist NS6740 on the Development of Nicotine
CPP.
Mice underwent 3 days of conditioning with either s.c. saline or nicotine (0.5mg/kg).Nicotine
produced a robust CPP in mice pre-treated with vehicle. The α7 silent agonist NS6740 (1 and 3
mg/kg; i.p.) did not reduce nicotine reward as measured by the CPP test at both doses tested. *
Denotes p<0.05 from vehicle-vehicle. Each point represents the mean ± SEM of n=7-10 mice per
group.
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α7 nAChR full orthosteric agonist PNU282987 attenuates somatic and affective nicotine
withdrawal signs
The physical (somatic signs and hyperalgesia) and affective (anxiety-related behavior) signs of
nicotine withdrawal were measured in mice following pretreatment with either PNU282987 or
vehicle 15 min prior to mecamylamine administration on day 15. Nicotine withdrawn mice had a
significantly increased anxiety-related behavior in the plus maze [F (5, 32) = 11.21, p< 0.0001]
(Fig. 8A), increased expression of somatic withdrawal signs [F (5, 32) = 24.48, p< 0.0001] (Fig.
8B), and decreased response latencies in the hot-plate test [F (5, 32) = 17.89, p< 0.0001] (Fig.
8C). Mice implanted with saline MPs and received vehicle expressed no withdrawal signs.
PNU282987 attenuated nicotine withdrawal signs in a dose related manner. Pretreatment with
PNU282987 exhibited a trend of reducing anxiety-like behavior (time in open arms in the plusmaze test) and reached significance at 9mg/kg (s.c.) (p<0.05) (Fig. 8A). In addition, pretreatment
with PNU282987 decreased nicotine somatic withdrawal signs and was statistically significant at
doses 3 and 9 mg/kg (p<0.05) (Fig. 8B). However, as the post hoc analysis showed, pretreatment
with PNU282987 was ineffective at attenuating the expression of hyperalgesia (hot-plate
latency) at all doses tested (p<0.05) (Fig. 8C). The highest dose of PNU282987 tested (9 mg/kg)
did not significantly affect behavioral responses in saline-infused mice in any withdrawal test.
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Figure 8: Effects of Full α7 Orthosteric Agonist PNU282987 on Physical and Affective
Signs of Precipitated Nicotine Withdrawal
Mice were chronically infused with saline or nicotine (24 mg/kg/day) for 14 days. On day 15
mice received s.c. injection of PNU282987 (1, 3 and 9 mg/kg) or vehicle. Mice then were
administered mecamylamine (2mg/kg; s.c.) 10 min prior to behavioral assessment of A) anxietylike behaviors (Time spent in the open arm), B) somatic signs, and C) hyperalgesia (hot plate
latency).Nicotine induced withdrawal symptoms: increased anxiety related behavior and somatic
signs, but decreased hot plate latency. Compared to vehicle, pretreatment with PNU282987: A)
attenuated the anxiety-like behavior at 9mg/kg; B) reduced somatic signs at 3 and 9mg/kg; and
C) and no effect on hot plate latency in nicotine withdrawn mice. Each point represents the mean
± S.E.M. of n=6–8 mice per group. * Denotes p< 0.05 vs. Saline MP group, # Denotes p< 0.05
vs. Nicotine MP group.
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α7 nAChR Orthosteric Full Agonist PNU282987 Did Not Alter Arm Crosses in the
Elevated Plus Maze.
To examine whether or not the results observed in the elevated plus maze test were possibly
confounded by alterations in locomotor activity induced by PNU282987 administration, the
number of arm crosses were recorded. As shown in Table 2 PNU282987 had no effect on the
number of arm crosses in the plus maze [F (5, 32) = 0.7950, p=0.5613].
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Table 2: PNU282987 does not have an effect on the average number of arm crosses in the
elevated plus maze test
Mice undergoing nicotine withdrawal received PNU282987 (1, 3 and 9 mg/kg; s.c.) or vehicle.
The average number of arm crosses were recorded in the plus maze test. The numbers are
presented as the total number of arm crosses ± SEM (n=8).

Treatment

Average number of arm crosses ±SEM

Saline MP-vehicle

6.8± 0.6

Saline MP- PNU282987 (9)

7.2±0.7

Nicotine MP- vehicle

7.5±0.9

Nicotine MP-PNU282987 (1)

6.2±0.7

Nicotine MP-PNU282987 (3)

6.5 ± 0.6

Nicotine MP-PNU282987 (9)

5.8±0.5
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Somatic nicotine withdrawal signs are attenuated by α7 nAChR Type I PAM NS1738
Physical and affective signs of nicotine withdrawal were measured in mice following
pretreatment with either NS1738 or vehicle 15 min prior to mecamylamine administration on day
15. Nicotine withdrawn mice had a significantly increased anxiety-related behavior in the plus
maze [F (4, 35) = 21.86, p<0.0001] (Fig. 9A), increased expression of somatic withdrawal signs
[F (4, 35) = 37.32, p<0.0001] (Fig. 9B), and decreased response latencies in the hot-plate test[F
(4, 35) = 5.208, p=0.0021] (Fig. 9C). Pretreatment with NS1738 had no effect on the expression
of anxiety-related behaviors (time in open arms in the plus-maze test) (p>0.05) (Fig. 9A).
However, NS1738 reduced nicotine somatic withdrawal signs at 10mg/kg (p<0.05) (Fig. 9B).
Pretreatment with NS1738 exhibited a trend of reversing hot plate latencies (measure of
hyperalgesia) but it did not reach significance at any of the doses tested(p>0.05) (Fig. 9C). The
highest dose of NS1738 (10 mg/kg) did not significantly affect behavioral responses in salineinfused mice in any withdrawal test.
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Figure 9: Effects of α7 Type I PAM NS1738 on Physical and Affective Signs of Precipitated
Nicotine Withdrawal
Mice were infused with saline or nicotine (24 mg/kg/day) for 14 days. On day 15 mice received
s.c. injection of NS1738 (1 and 10 mg/kg) or vehicle. Mice then were administered
mecamylamine (2mg/kg; s.c.) 10 min prior to behavioral assessment of A) anxiety-like behaviors
(Time spent in the open arm), B) somatic signs, and C) hyperalgesia (hot plate latency). Nicotine
induced withdrawal symptoms: increased anxiety related behavior and somatic signs, but
decreased hot plate latency. Compared to vehicle, pretreatment with NS1738: A) did not
attenuate the anxiety-like behavior at any dose tested; B) reduced somatic signs at 10mg/kg; and
C) and had no effect on hot plate latency in nicotine withdrawn mice. Each point represents the
mean ± S.E.M. of n=6–8 mice per group. * Denotes p< 0.05 vs. Saline MP group, # Denotes p<
0.05 vs. Nicotine MP group.
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α7 nAChR Type I PAM NS1738 Did Not Alter Arm Crosses in the Elevated Plus Maze.
To examine whether or not the results observed in the elevated plus maze test was possibly
confounded by alterations in locomotor activity induced by NS1738 administration, the number
of arm crosses were recorded. As shown in Table 3 NS1738 had no effect on the number of arm
crosses in the plus maze [F (4, 35) = 0.7950, p=0.9962].
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Table 3: NS1738 does not have an effect on the average number of arm crosses in the
elevated plus maze test
Mice undergoing nicotine withdrawal received NS1738 (1 and 10 mg/kg; i.p.) or vehicle. The
average number of arm crosses were recorded in the plus maze test. The numbers are presented
as the total number of arm crosses ± SEM (n=8).

Treatment

Average number of arm crosses ±SEM

Saline MP-vehicle

9.9± 1.8

Saline MP- NS1738 (10)

9.6±1.4

Nicotine MP- vehicle

10.1±1.4

Nicotine MP-NS1738 (1)

9.4±1.7

Nicotine MP-NS1738 (10)

9.4 ± 1.4
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Nicotine withdrawal-induced hyperalgesia attenuated by α7 nAChR Type II PAM
PNU120596
Physical and affective signs of nicotine withdrawal were measured in mice following
pretreatment with either PNU120596 or vehicle 15 min prior to mecamylamine administration on
day 15. Nicotine withdrawn mice had a significantly increased anxiety-related behavior in the
plus maze [F (4, 29) = 3.730, p= 0.0144](Fig.10A), increased expression of somatic withdrawal
signs [F (4, 30) = 19.92, p<0.0001] (Fig. 10B), and decreased response latencies in the hot-plate
test [F (4, 30) = 6.808, p= 0.0005] (Fig. 10C). Pretreatment with PNU120596 had a tendency to
decrease the expression of anxiety-related behaviors (time in open arms in the plus-maze test),
however neither dose used altered anxiety-like behaviors significantly (p>0.05) (Fig. 10A). In
addition, PNU120596 at all doses used was ineffective at reducing nicotine somatic withdrawal
signs (p>0.05) (Fig. 10B). However, pretreatment with PNU120596 exhibited a trend of
reversing hot plate latencies (measure of hyperalgesia) and significantly increased hot plate
latencies at 9mg/kg (p<0.05) (Fig. 10C). The highest dose of PNU120596 (9 mg/kg) did not
significantly affect behavioral responses in saline-infused mice in any withdrawal test.
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Figure 10: Effects of Type II PAM PNU120596 on Physical and Affective Signs of
Precipitated Nicotine Withdrawal
Mice were chronically infused with saline or nicotine (24 mg/kg/day) for 14 days. On day 15
mice received i.p. injection of PNU120596 (3 and 9 mg/kg) or vehicle. Mice then were
administered mecamylamine (2mg/kg; s.c.) 10 min prior to behavioral assessment of A) anxietylike behaviors (Time spent in the open arm), B) somatic signs, and C) hyperalgesia (hot plate
latency).Nicotine induced withdrawal symptoms: increased anxiety related behavior and somatic
signs, but decreased hot plate latency. Compared to vehicle, pretreatment with PNU120596: A)
had no effect anxiety-like behavior; B) had no effect on somatic signs; and C) but significantly
increased hot plate latency at 9mg/kg in nicotine withdrawn mice. Each point represents the
mean ± S.E.M. of n=6–8 mice per group. * Denotes p< 0.05 vs. Saline MP group, # Denotes p<
0.05 vs. Nicotine MP group.
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α7 nAChR Type II PAM PNU120596 Did Not Alter Arm Crosses in the Elevated Plus
Maze.
To examine whether or not the results observed in the elevated plus maze test was possibly
confounded by alterations in locomotor activity induced by PNU120596 administration, the
number of arm crosses were recorded. As shown in Table 4 PNU120596 had no effect on the
number of arm crosses in the plus maze [F (5, 32) = 0.5965, p=0.6682].
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Table 4: PNU120596 does not have an effect on the average number of arm crosses in the
elevated plus maze test
Mice undergoing nicotine withdrawal received PNU120596 (3 and 9 mg/kg; i.p.) or vehicle. The
average number of arm crosses were recorded in the plus maze test. The numbers are presented
as the total number of arm crosses ± SEM (n=8).

Treatment

Average number of arm crosses ±SEM

Saline MP-vehicle

7.5± 0.9

Saline MP- PNU120596 (9)

6.9±0.8

Nicotine MP- vehicle

7.8±0.8

Nicotine MP-PNU120596 (3)

6.5±0.4

Nicotine MP-PNU120596 (9)

7.9 ± 0.9
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D. Discussion
The results of this study produced interesting findings about the impact of α7 nAChR
modulation and conformations on nicotine reward and withdrawal in mice. The α7 full
orthosteric agonist PNU282987 and the Type II α7 nAChR PAM PNU120596 reduced nicotine
CPP (Fig. 4 and 6) while the silent agonist NS6740 and Type I PAM NS1738 had no effect (Fig.
5 and 7). In nicotine withdrawal, PNU282987, NS1738, and PNU120596 attenuated different
signs of the withdrawal syndrome (Fig.8, 9 and 10). To our knowledge, this is the first report of
α7 nAChR PAMs and a silent agonist used in preclinical nicotine dependence tests.
In the presence of an orthosteric full agonist, the α7 nAChR has a low probability of
opening, is permeable to calcium and rapidly desensitizes42,50. These intrinsic factors may limit
the usefulness of α7 nAChR ligands; therefore, PAMs were developed as pharmacological tools
to circumvent the intrinsic limitations of the α7 nAChR. The probability of an α7 nAChR being
open is less than one in a million

51

, thus the Type I PAM NS1738 and Type II PAM

PNU120596 , which increase the probability of channel opening, were used to evaluate the role
of this α7 nAChR feature in nicotine CPP. In comparison to the traditional orthosteric agonist
PNU282987, which attenuated nicotine CPP at 9mg/kg, PNU120596 reduced nicotine CPP at
both doses used (1 and 9mg/kg). PNU120596 may be more potent than PNU282987 in the
nicotine CPP test. Utilizing multiple doses of these compounds will further characterize this
observation. NS1738 had no effect on nicotine at both doses tested (1 and 10mg/kg). This
suggests that the Type I PAM NS1738 does not reveal the anti-reward endogenous tone mediated
by α7 nAChRs with an increased probability of channel opening. The divergent effects of the
Type I and Type II PAM may be the result of PNU120596’s ability to decrease the rate of
desensitization. PNU120596 not only increases the chance of ion conductance but also allows
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the channel to remain in the open state for a longer duration, which also results in an increase of
possible ion conductance. Attenuating the desensitization rate of the endogenous tone by
PNU120596 was sufficient to induce an effect in nicotine CPP. Similar findings with NS1738
and PNU120596 were shown in a mouse model of tonic pain. The Type II PAM PNU120596,
but not the Type I PAM NS1738, reduced pain-related behaviors in the early and late phase of
the formalin test

240

. Nicotine CPP is a CNS-mediated effect

36,139

, thus, the lack of effect of

NS1738 may be due to poor blood brain barrier penetrability. However, systemic administration
of NS1738 at similar doses used in our study produced brain concentrations
to enhance the channel opening of acetylcholine in vitro

249

240

that were shown

. In addition, it has been previously

reported that NS1738 treated mice do not exhibit any motor impairments or alterations in their
locomotor activity

286

. This current study also confirms the lack of effect of NS1738 on

locomotor activity as indicated by the number of crossovers in the elevated plus maze (see Table
3). Furthermore, there are thought to be at least two types of desensitization states for the α7
nAChR: Type II modulator sensitive and Type II modulator insensitive

42

. NS1738 and

PNU120596 may induce different desensitization states, which may be responsible for the
divergent results. However, differentiation and effects of these two type of desensitization states
are unknown in vivo. Our results with the silent agonist NS6740 (1 and 3mg/kg), which induces
the receptor into a desensitized state with the absence of an open state, did not alter nicotine
CPP. Higher doses of NS6740 were not use due to aversion it caused on its own. NS6740 is
effective at reducing chronic pain and inflammation in mice
cognitive assays

245

246

; however, it lacked efficacy in

. This suggests that centrally mediated effects of nicotine may require ion

conductance of α7 nAChRs.
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In our nicotine withdrawal experiments the orthosteric agonist PNU282987 attenuated anxietylike behaviors (Fig.8); however, the α7 nAChR PAMs NS1738 and PNU120596 had no effect on
anxiety-like behavior as observed in the elevated plus maze (Fig. 9 and 10). This suggests that
low probability of channel opening and rapid desensitization are needed for this effect. Our
results are in agreement with a recent study of α7 nAChR activation with the α7 orthosteric
agonist ABT-107 which was shown to also attenuate anxiety-like behaviors in the NIH test

267

.

However, in another study α7 nAChR KO mice that received 36mg/kg/day of nicotine for 14
days and underwent precipitated withdrawal, did not show alterations in anxiety-related
behaviors or CPA 93. It has been previously shown in reward studies that α7 KO mice may have
an increased sensitivity to nicotine at lower doses
typical rewarding doses

37

35

and this sensitivity is undetectable at higher

. Thus, the lack of alteration of anxiety-like behavior in the α7 KO

mice may be due to the high dose of nicotine given to mask an effect. Indeed, a lower dose such
as 24mg/kg/day of nicotine for 14 days has also been shown to produce reliable nicotine
withdrawals 89,182 and this dose is used in the current study.
The orthosteric full agonist PNU282987 and the Type I PAM NS1738 both attenuated somatic
signs, but the Type II PAM PNU120596 had no effect on somatic signs. This may suggest that
rapid desensitization is necessary for the attenuation of somatic signs by α7 nAChRs. It has been
shown that α7 nAChR KO mice undergoing nicotine withdrawal have a reduction in somatic
signs

94

,implicating the importance of

α7 nAChR blockade or desensitization in nicotine

dependence. However, another study from our lab that measured the same somatic signs did not
see a reduction in somatic signs observed in α7 KO mice compared to their WT littermates

93

.

This discrepancy may be contributed to the different somatic signs observed in the studies. The
latter study observed somatic signs such as paw tremors, body tremors, and backing while the
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former study tallied signs such as grooming, scratching, and chewing. Therefore, the somatic
sign results should be interpreted with caution.
PNU120596 was the only α7 ligand that reduced nicotine withdrawal-induced hyperalgesia in
the hot plate test. It is unclear of the reason for this reduction of hyperalgesia by PNU120596 and
the lack of effect of PNU282987. Previous studies implicate the α7 nAChR in the reduction of
hyperalgesia evidenced in nicotine withdrawn α7 KO mice

93,187

antagonist MLA has been shown to precipitate hyperalgesia

89

. In contrast, the α7 nAChR

. This effect may be to the

antagonism of MLA at off-target effects such as α6*, α3*, β3* nAChRs 258. To further evaluate
the role of α7 nAChR desensitization in nicotine withdrawal, the silent agonist NS6740 should
be utilized.
Taken together, our results suggests that desensitization/ion conductance and channel
opening of the α7 nAChR play important roles in nicotine dependence behaviors in mice. In
addition, the utilization of PAMs in this study suggests that endogenous acetylcholine/ choline
tone is sufficient to attenuate some aspects of nicotine withdrawal. These findings highlight a
beneficial effect of using α7 PAMs instead of α7 orthosteric agonists. PAMs may provide less
overstimulation to the endogenous cholinergic system because activation will only occur in the
presence of acetylcholine release. In addition, PAMs also provide better selectivity for α7
nAChRs. They interact with an allosteric site of the receptor and α7 nAChRs and serotonin 5HT3 receptors have a high homology of their ligand binding domain

237

. The silent agonist

NS6740 used in this study aided to understand the role of desensitization and ion conductance of
the α7 nAChR. PAMs and silent agonists may serve as useful tools to understand the effect of α7
nAChR modulation in nicotine dependence.
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CHAPTER THREE

In vivo Interactions between α7 Nicotinic Acetylcholine Receptor and Nuclear Peroxisome
Proliferator-Activated Receptor-α: Implication for Nicotine Dependence
The published article below with the addition of two supplemental figures (Fig. 14 and Fig. 18)
was used for chapter three.
Jackson A, Bagdas D, Muldoon PP, Lichtman AH, Carroll FI, Greenwald M, Miles MF,
Damaj MI. In vivo interactions between α7 nicotinic acetylcholine receptor and nuclear
peroxisome

proliferator-activated

receptor-α:

Implication

for

nicotine

dependence.

Neuropharmacology. 2017 Mar 7;118:38-45.

A. Introduction
The homomeric α7 nicotinic acetylcholine receptor (nAChR) has been shown to play a role in
cognition, inflammation, immunity and neuroprotection

247

. Recent findings suggest this low

affinity α7 nAChR modulates nicotine reward and reinforcement in rodents

30,35

. The α7 nAChR

selective agonist PNU282987 infused locally into the nucleus accumbens (NAc) shell reduced
intravenous self-administered nicotine in rats. In contrast, ArIB, an α7 selective nAChR
antagonist, infused in the NAc increased nicotine intake 30. Similarly, the genetic deletion of α7
nAChRs in mice enhances nicotine reward as measured in the CPP test, whereas α7 knock-in
(producing mice heterozygous for a Leu250-to-Thr substitution in the channel domain of α7
subunit, which creates a gain-of-function mutation) abolishes nicotine preference. In addition,
the selective α7 agonist PHA-543613 blocked the development of nicotine CPP in mice

35

.

Attenuation of nicotine reward and reinforcement by α7 nAChR agonists seems to be associated
with a decreased nicotine-induced dopaminergic transmission in the brain, as PNU282987 blocks
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nicotine-induced increased firing activity of the ventral tegmental area (VTA) dopamine neurons
in rats 116.
This important effect of α7 nAChR modulation of nicotine reward has prompted studies
of the underlying mechanism. It has been suggested that α7 nAChR activation regulates VTA
dopaminergic cells via the PPARα in the rat. The α7 nAChR agonist PNU282987 induced
synthesis of two fatty acid PPARα endogenous ligands, OEA and PEA, that in turn activate
PPARα and phosphorylate β2-containing nAChRs on dopamine neurons via a tyrosine kinase
pathway 116. These findings suggest a pathway by which α7 nAChR pharmacological stimulation
indirectly inactivates β2-containing nAChRs via PPARα receptors. However, the above-noted
study did not directly investigate this mechanism using a nicotine reward paradigm which is
imperative because β2-containing nAChRs are required for nicotine reward 37,135.
PPARα is a nuclear ligand-activated transcription factor that when activated, enhances
transcription of various genes involved in modulating many peripheral physiological responses
such as inflammation and lipolysis
associated with reward

287–289

276

. Importantly, PPARαs, which are located in brain regions

, have been shown to modulate the rewarding properties of abused

substances such as alcohol and nicotine
attenuates nicotine

34,154,277

115,290

. Acute administration of PPARα agonists

and alcohol reinforcement

induced dopamine firing in rodents

115

290

, alcohol intake

291,292

and nicotine-

. For example clofibrate, a lipid lowering agent and

PPARα agonist 293, was shown in rats to block acquisition of nicotine seeking, decrease nicotine
intravenous self-administration and block nicotine-induced dopamine release into the NAc shell
34

. Therefore, we hypothesize that PPARα may serve as a downstream mediator of α7 nAChR

activation in nicotine reward. To test this hypothesis the present study investigated the
interaction of the α7 nAChR and PPARα in a preclinical mouse model of reward (nicotine CPP).
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Furthermore, we examined PPARα activation in nicotine CPP and nicotine withdrawal, a
behavioral outcome not measured before in preclinical studies with PPARα activators. We
compared effects of the selective and potent PPARα agonist WY-14643 294,295 with a commonly
used lipid lowering fibrate medication that activates PPARα, fenofibrate

296

. Results from these

experiments may provide insight into the roles of α7 nAChR and PPARα in nicotine dependence.
B. Materials and Methods
Animals
ICR male mice (8 weeks upon arrival; Harlan Laboratories, Indianapolis, IN) served as subjects.
Mice were housed four per cage with ad libitum access to food and water on a 12-h light cycle in
a humidity and temperature controlled vivarium that was approved by the Association for
Assessment and Accreditation of Laboratory Animal Care. Mice received corn cob bedding and
were fed Envigo Teklad mouse/rat diet 7102 (LM-485). Experiments were performed during
the light cycle and were approved by the Institutional Animal Care and Use Committee of
Virginia Commonwealth University and followed the National Institutes of Health Guidelines
for the Care and Use of Laboratory Animals.

Drugs
(−)-Nicotine hydrogen tartrate [(−)-1-methyl-2-(3- pyridyl) pyrrolidine (+)-bitartrate] and
mecamylamine HCl (non-selective nAChR antagonist) were purchased from Sigma-Aldrich Inc.
(St. Louis, MO, USA). PNU282987 (α7 nAChR agonist) and cocaine HCl were provided by the
Drug Supply Program of the National Institute on Drug Abuse (Rockville, MD). Drugs were
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dissolved in physiological saline and administered systemically (s.c. for nicotine,
mecamylamine, PNU282987 and i.p. for cocaine). Fenofibrate (PPARα agonist), WY-14643
(PPARα agonist), and GW6471 (PPARα antagonist) and MK886 (PPARα antagonist) were
purchased from Tocris (Minneapolis, MN) and dissolved in a mixture of 1:1:18 [1 volume
ethanol/1 volume Emulphor-620 (Sanofi-Aventis, Bridgewater, NJ) and 18 volumes saline] and
administered i.p. Drug solutions were prepared in 10 ml solutions (i.e. 3mg of drug in 10ml of
vehicle indicates 3mg/kg dose). Freshly prepared solutions were injected at a total volume of 1
ml/100g of body weight. Doses are expressed as the free base of the drug.
Nicotine and cocaine conditioned preference studies
An unbiased CPP paradigm was performed as we previously described 80,284. Briefly, the CPP
apparatus consisted of three chambers in a linear arrangement (ENV3013; Med Associates, St
Albans, VT). The external white and black chambers (20×20×20 cm each) differed in overall
color and floor texture (white mesh or black rod), and were separated by a smaller gray chamber
with a smooth PVC floor. Partitions could be removed to allow access from the gray chamber to
the black and white chambers. On day 1 animals were confined to the middle chamber for a 5
min habituation and then allowed to freely move between all three chambers for 15 min. Time
spent in each chamber was recorded and these data were used to populate groups of
approximately equal bias in baseline chamber preference. Twenty-minute conditioning sessions
occurred twice a day (days 2–4).
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The nicotine group received nicotine in one large chamber and saline in the other large chamber.
Treatments were counterbalanced to ensure some mice received the unconditioned stimulus in
the morning and others received it in the afternoon. The nicotine paired chamber was
randomized across groups. Sessions were 4 hr apart and were conducted by the same
investigator. On test day (day 5) mice could access all chambers for 15 min in a drug free state.
The preference score was calculated by determining the difference between time spent in the
drug paired side on the test day versus the time in drug paired side on the baseline day. Any
mouse showing preference for one side higher than 65% was not used in the study.

Nicotine Precipitated Withdrawal Studies
A well-established and validated nicotine withdrawal model was performed 89,94,182,297.Mice were
infused with 24mg/kg/day nicotine or saline for 14 days using s.c. osmotic MPs (model 2000;
Alzet Corporation, Cupertino, CA) implanted under isoflurane anesthesia

93

.Nicotine

concentration was adjusted according to animal weight and mini pump flow rate. On the morning
of day 15 mice were pretreated with vehicle, WY-14643 (0.3, 1 and 5 mg/kg, i.p.; 15 min prior)
or fenofibrate (50 and 100 mg/kg, i.p.;1 hr prior) before challenge with the nonselective nAChR
antagonist mecamylamine (2 mg/kg; s.c.) to precipitate withdrawal. Affective (anxiety-like
behavior) and physical (somatic signs and hyperalgesia) nicotine withdrawal signs were
evaluated 10 min later as described in 93. Mice were first evaluated for 5 min in the elevated plus
maze test for anxiety-related behavior. Time spent on the open arms of the plus maze was used
as a measure of anxiety-related response. The number of crosses between open and closed arms
was counted as a measure of locomotor activity. The plus maze assessment was immediately
followed by a 20 min observation of somatic signs measured as paw and body tremors, head
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shakes, backing, jumps, curls and ptosis. Mice were placed in clear activity cages without
bedding for the observation period. The total number of somatic signs was tallied for each mouse
and the average number of somatic signs during the observation period was plotted for each test
group. Hyperalgesia was evaluated using the hot plate test immediately following the somatic
sign observation period. Mice were placed into a 10-cm wide glass cylinder on a hot
plate(Thermojust Apparatus, Richmond, VA) maintained at 52°C. The latency to reaction time
(jumping or paw licking) was recorded. The specific testing sequence was chosen based on our
prior studies showing that this order of testing reduced within-group variability and produced the
most consistent results

93

. All studies were performed by an observer blinded to experimental

treatment.
Statistical analysis
Data were analyzed using the GraphPad software version 6.0 (GraphPad Software, Inc., La
Jolla, CA) and expressed as the mean ± S.E.M. A one-way analysis of variance (ANOVA) in
conjunction with Holm-Šídák comparison tests were conducted to determine significant effects
of drug treatments vs controls. Two-way ANOVA followed by the Tukey multiple comparisons
test was used in order to evaluate attenuation of dose response of nicotine CPP by PPARα
agonist WY-14643. Comparisons were considered statistically significant when p < 0.05.
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C. Results
Development of Nicotine CPP Attenuated by α7 nAChR Full Agonist PNU282987
Mice were conditioned with either saline or nicotine (0.5 mg/kg; s.c.) for 3 days in the CPP
paradigm. The 0.5mg/kg dose of nicotine has been previously shown to produce a significant
preference in the CPP test

37,78

. In Fig. 11 a robust CPP was observed in nicotine–conditioned

mice pre-treated with vehicle [F(4, 33) = 16.29, p < 0.0001]. PNU282987 given 15 min prior to
nicotine, reduced nicotine reward. As revealed by the Holm-Šídák comparison tests, PNU282987
(3mg/kg) significantly altered nicotine CPP (p<0.05), but was ineffective at the lower dose of
0.6mg/kg (p>0.05). PNU282987 at the dose of 3 mg/kg did not produce a preference in saline
treated-mice.
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Figure 11: Attenuation of the Development of Nicotine CPP by α7 nAChR Orthosteric Full
Agonist PNU282987
Mice were conditioned with either s.c. saline or nicotine (0.5mg/kg) for 3 days. A robust CPP
was observed in nicotine-conditioned mice pre-treated with vehicle. The α7 agonist, PNU282987
(0.6 and 3 mg/kg; s.c.) reduced nicotine reward as measured by the CPP test. * Denotes p<0.05
from vehicle-vehicle. # Denotes p<0.05 from nicotine control. Each point represents the mean ±
SEM of n=6-8 mice per group.
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PPARα Antagonist Blocks α7 nAChR Agonist PNU282987 in Nicotine CPP
The PPARα antagonist GW6471 was utilized to evaluate the PPARα dependency of α7 nAChR
activation in nicotine CPP. In Fig. 12 male ICR mice conditioned with 0.5mg/kg s.c. of nicotine
for three days exhibited a significant preference [F (7, 52) = 7.459, p<0.0001]. One-way
ANOVA revealed that pretreatment with the α7 nAChR agonist PNU282987 (3mg/kg; s.c.)
given 15 min prior to nicotine attenuated nicotine CPP. This attenuation was significantly
blocked by the PPARα antagonist GW6471 (2mg/kg; i.p) administered 30 min prior to
PNU282987 (p<0.05), whereas GW6471 did not have an effect on nicotine CPP (p>0.05).
PNU282987 and GW6471 did not cause aversion or preference on their own or in combination.
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Figure 12: Interaction between PPARα and α7 nAChR in the Nicotine Reward.
Mice were conditioned with either s.c. saline or nicotine (0.5mg/kg) for 3 days. A robust CPP
was observed in nicotine-conditioned mice pre-treated with vehicle. The α7 agonist PNU282987
(mg/kg; s.c.) reduced nicotine reward. The PPARα antagonist GW6471 (2 mg/kg; i.p.) blocked
the effect of the α7 nAChR agonist in nicotine CPP. * Denotes p<0.05 from vehicle-vehicle; #
denotes p<0.05 from nicotine control. Φ Denotes p<0.05 from vehicle-PNU282987-nicotine.
Each point represents the mean ± SEM of n=6-9 mice per group
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The PPARα Agonist WY-14643 Attenuated Nicotine CPP
We then tested the impact of direct activation of PPARα using the selective and potent PPARα
agonist WY-14643 on nicotine CPP. Mice were conditioned with either saline or nicotine (0.5
mg/kg) for 3 days in the CPP paradigm. In Fig. 13 a robust CPP was observed in nicotine
conditioned mice pre-treated with vehicle [F (5, 36) = 26.27, p<0.0001]. WY-14643 reduced
nicotine reward in a dose-dependent manner at all doses tested (0.3, 0.6 and 1 mg/kg) (p<0.05).
On its own WY-14643 did not produce a preference or aversion in saline treated mice.
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Figure 13. PPARα Agonist WY-14643 Attenuated Nicotine CPP.
Mice were conditioned with either s.c. saline or nicotine (0.5 mg/kg) for 3 days. A robust CPP
was observed in nicotine-conditioned mice pre-treated with vehicle. An i.p. injection of PPARα
agonist WY-14643 (0.3, 0.6, and 1 mg/kg) reduced nicotine reward as measured by the CPP test.
*Denotes p<0.05 from vehicle control; #Denotes p<0.05 from nicotine control. Each point
represents the mean ± SEM of n=6-8 mice per group.
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The PPARα Antagonist Blocked the Effects of the PPARα Agonist WY-14643 in Nicotine
CPP
The PPARα antagonist, MK886, was used to investigate the PPARα-dependency of WY-14643.
At the highest effective dose, the PPARα agonist WY-14643 (1mg/kg; i.p.) significantly reduced
nicotine preference [F (2, 19) = 46.40, p <0.0001] (Fig. 14) and the PPARα antagonist MK886
(6mg/kg; i.p.), given 30 min prior to WY-14643 in the nicotine CPP test, completely blocked the
effect of WY-14643 (p<0.05). WY-14643 and MK886 did not produce a preference or aversion in
saline treated-mice [F (2, 17) = 0.9040, p <0.4235].
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Figure 14. The Effect of PPARα Antagonist MK886 on WY-14643 in Nicotine CPP.
Mice were conditioned with either s.c. saline or nicotine (0.5 mg/kg) for 3 days. A robust CPP
was observed in nicotine-conditioned mice pre-treated with vehicle The PPARα antagonist
MK886 (6 mg/kg; i.p.) blocked the effect of WY-14643 (1 mg/kg, i.p.) in nicotine CPP.*
Denotes p<0.05 from vehicle control; # Denotes p<0.05 from nicotine control. Each point
represents the mean ± SEM of n=6-8 mice per group.
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WY-14643 Did Not Shift the Potency of Nicotine in Nicotine CPP
To test the effect of the PPARα agonist WY-14643 on the potency of nicotine in the CPP test
WY-14643 (1 mg/kg; i.p.) was administered 15 minutes prior to nicotine (0.1, 0.5 and 1 mg/kg;
s.c.) in the CPP test. Two-way ANOVA revealed that a significant nicotine preference [F (3,
53) = 9.225, p <0.0001], a significant blockage of nicotine preference by WY-14643 [F (1,
53) = 44.54, p <0.0001] and interaction [F (3, 53) = 4.315, p =0.0085]. In Fig. 15 nicotine
preference was significant at 0.5 and 1mg/kg doses after 3 days of conditioning (p< 0.001). WY14643 pretreatment significantly attenuated nicotine preference at 0.5 and 1mg/kg (p< 0.05) and
had no effect on the 0.1 mg/kg dose of nicotine (p>0.05). WY-14643 did not produce preference
or aversion on its own (p>0.05).
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Figure 15. WY-14643 Attenuated Multiple Doses of Nicotine in the CPP test.
To evaluate blockade of dose response of nicotine CPP by PPARα agonist mice were
conditioned with either saline or nicotine (0.1, 0.5 and 1 mg/kg; s.c.) for 3 days. A robust CPP
was observed in nicotine-conditioned mice pre-treated with vehicle by the dose of 0.5 mg/kg or
above. Pretreatment with WY-14643 (1 mg/kg; i.p.) reduced nicotine-CPP at the dose of 0.5 and
1 mg/kg nicotine. * Denotes p<0.05 from vehicle control; # Denotes p<0.05 from nicotine
control. Each point represents the mean ± SEM of n=6-8 mice per group.
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PPARα Agonist WY-14643 Did Not Attenuate Cocaine CPP
To test for the behavioral selectivity of WY-14643 on nicotine CPP, WY-14643 was evaluated in
cocaine CPP as previously described139,298. In Fig. 16 robust preferences for cocaine (10mg/kg;
i.p.) and nicotine (0.5mg/kg; s.c.) were produced after 3 days of conditioning in mice [F (4, 32) =
32.63, p <0.0001]. The 10 mg/kg dose of cocaine has been previously shown to produce a
significant preference in the CPP test

159,299

. Although WY-14643, with a 15 min pretreatment,

totally reduced nicotine reward at 1mg/kg as previously observed in this study (p<0.05) , it had
no significant effect on cocaine preference (p>0.05).
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Figure 16. Effects of PPARα Agonist WY-14643 on Nicotine and Cocaine CPP.
To test the selectivity of the attenuating effect of the PPARα agonist in nicotine CPP a separate
group of mice was conditioned with saline, cocaine (10 mg/kg; i.p.) or nicotine (0.5 mg/kg; s.c.)
for 3 days. A robust CPP was observed in both nicotine conditioned and cocaine-conditioned
mice pre-treated with vehicle. The PPARα agonist WY- 14643 (1mg/kg; i.p.) reduced nicotine
reward, but not cocaine reward as measured by the CPP test. * Denotes p<0.05 from vehicle
control; # Denotes p<0.05 from nicotine control. Each point represents the mean ± SEM of n=68 mice per group
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Clinically Used PPARα Agonist Fenofibrate Reduced Nicotine CPP
We utilized the clinically available PPARα agonist fenofibrate in the nicotine CPP paradigm. As
previously observed in this study one way ANOVA showed that nicotine induced a significant
preference in comparison to saline-treated mice after the 3-day conditioning period [F (6, 45) =
4.078, p=0.0024]. In Fig. 17 pretreatment with lower doses of fenofibrate (1 and 9 mg/kg) 1hr
prior to nicotine did not significantly alter nicotine CPP (p>0.05). However, the dose of 50
mg/kg of fenofibrate reduced nicotine preference significantly (p<0.05). The effect of fenofibrate
was loss at 100mg/kg (p>0.05). Fenofibrate had no effect on its own in saline treated-mice.
Fenofibrate was administered at doses previously described 291,292.
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Figure 17. Effect of PPARα Agonist Fenofibrate on Nicotine CPP
Mice were conditioned with either s.c. saline or nicotine (0.5mg/kg) for 3 days. A robust CPP
was observed in nicotine conditioned mice pre-treated with vehicle. Fenofibrate (1, 9,50 and 100
mg/kg; i.p.), clinically used PPARα agonist, reduced nicotine reward as measured by the CPP
test. *Denotes p<0.05 from vehicle control; # Denotes p<0.05 from nicotine control. Each point
represents the mean ± SEM of n=6-8 mice per group.
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The PPARα Antagonist Did Not Block Fenofibrate in Nicotine CPP
The PPARα antagonist, MK886, was also used to investigate the PPARα-dependency of
fenofibrate. MK886 was used to be consistent with previous studies utilizing another PPARα
agonist of the fibrate family, clofibrate in nicotine reward

34

. At the highest effective dose used

fenofibrate (50mg/kg; i.p.), with 1 hr pretreatment, significantly attenuated nicotine preference [F
(5, 36) = 3.835, p =0.0069] (Fig. 18), but the PPARα antagonist MK886 (6mg/kg; i.p.) had no
effect on fenofibrate in nicotine CPP (p>0.05, Fig.18). Fenofibrate and MK886 did not produce a
preference or aversion in saline treated-mice.
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Figure 18. The Effect of PPARα Antagonist MK886 on Fenofibrate in Nicotine CPP
Mice were conditioned with either s.c. saline or nicotine (0.5mg/kg) for 3 days. A robust CPP
was observed in nicotine-conditioned mice pre-treated with vehicle. The PPARα antagonist
MK886 (6 mg/kg; i.p.) did not block the effect of fenofibrate (50mg/kg; i.p.) in nicotine CPP. *
Denotes p<0.05 from vehicle control; # Denotes p<0.05 from nicotine control. Each point
represents the mean ± SEM of n=6-8 mice per group.
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Nicotine Withdrawal Signs Attenuated by PPARα Agonist WY-14643
The physical (somatic signs and hyperalgesia) and affective (anxiety-related behavior) signs of
nicotine withdrawal were measured in mice following pretreatment with either WY-14643 or
vehicle 15 min prior to mecamylamine administration on day 15. In Fig 19 nicotine withdrawn
mice had a significantly increased anxiety-related behavior in the plus maze[F (5, 32) = 4.853,
p=0.0020] (Fig. 19A), increased expression of somatic withdrawal signs[F (5, 33) = 24.04,
p<0.0001] (Fig. 19B) and decreased response latencies in the hot-plate test [F (5, 34) = 3.432,
p=0.0129] (Fig.19C) compared to control mice implanted with saline MPs. In Fig. 19A one-way
ANOVA revealed that pretreatment with WY-14643 attenuated anxiety-like behavior (time in
open arms in the plus-maze test) at the dose of 5 mg/kg (p<0.05). In addition, as shown in Fig.
19B pretreatment with 1 and 5 mg/kg of WY-14643 decreased nicotinic somatic withdrawal
signs (p<0.05). In our study somatic signs were expressed as followed: paw tremors (~70%),
body tremors (~5%), head shakes (~10%), backing (~15%). WY-14643 reduced these individual
somatic signs in a uniformed manner. Finally, in Fig. 19C pretreatment with WY-14643 also
attenuated the expression of hyperalgesia (hot-plate latency) at 5 mg/kg (p<0.05). The highest
dose of WY-14643 tested (5 mg/kg) did not significantly affect behavioral responses in salineinfused mice in any withdrawal test.
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Figure 19: Effects of PPARα Agonist WY-14643 on Physical and Affective Signs of
Precipitated Nicotine Withdrawal.
Mice were chronically infused with saline or nicotine (24 mg/kg/day) for 14 days. On day 15
mice received i.p. injection of WY-14643 (0.3, 1 and 5 mg/kg) or vehicle. Mice then were
administered mecamylamine (2mg/kg; s.c.) 10 min prior to behavioral assessment of A) anxietylike behaviors (Time spent in the open arm), B) somatic signs, and C) hyperalgesia (hot plate
latency).Nicotine induced withdrawal symptoms: increased anxiety related behavior and somatic
signs, but decreased hot plate latency. Compared to vehicle, pretreatment with WY-14643: A)
attenuated the anxiety-like behavior at 5mg/kg; B) reduced somatic signs at 1 and 5mg/kg; and
C) significantly increased hot plate latency at 5mg/kg in nicotine withdrawn mice. Each point
represents the mean ± S.E.M. of n=6–8 mice per group. * Denotes p< 0.05 vs. Saline MP group,
# Denotes p< 0.05 vs. Nicotine MP group.
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PPARα Agonist WY-14643 Did Not Alter Arm Crosses in the Elevated Plus Maze.
To examine whether or not the results observed in the elevated plus maze test was possibly
confounded by alterations in locomotor activity induced by WY-14643 administration, the
number of arm crosses were recorded. As shown in Table 5 WY-14643 had no effect on the
number of arm crosses in the plus maze [F (5, 32) = 0.4386, p=0.8182].
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Table 5: WY-14643 does not significantly alter the average number of arm crosses in the
elevated plus maze test
Mice undergoing nicotine withdrawal received WY-14643(0.3,1, 5; i.p.) or vehicle. The average
number of arm crosses were recorded in the plus maze test. The numbers are presented as the
total number of arm crosses ± SEM (n=6-8).

Treatment

Average number of arm crosses ±SEM

Saline MP-vehicle

7.8± 0.9

Saline MP- WY-14643 (5)

8±0.8

Nicotine MP-vehicle

7.1±0.4

Nicotine MP-WY-14643 (0.3)

7.2±0.3

Nicotine MP-WY-14643 (1)

7.2±0.3

Nicotine MP-WY-14643 (5)

7.7±0.5
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Fenofibrate Modestly Attenuated Nicotine Withdrawal
Fenofibrate was administered 1 hr prior to mecamylamine on day 15 after 14 days of continuous
nicotine exposure via osmotic MPs. Following mecamylamine administration nicotine
withdrawals signs (anxiety-like behavior, somatic signs and hyperalgesia) were measured in
mice. In Fig. 20 nicotine withdrawn mice displayed an increase in anxiety-related behavior in
the plus maze [F (5, 42) = 22.08, p<0.0001] (Fig. 20A), enhanced expression of somatic
withdrawal signs [F (5, 42) = 63.26, p<0.0001] (Fig. 20B) and attenuated response latencies in
the hot-plate test [F (5, 42) = 12.12, p<0.0001](Fig. 20C) in comparison to their saline MPimplanted counterparts. In Fig. 20A one way ANOVA revealed that pretreatment with
fenofibrate had no effect on anxiety-like behavior (time in open arms in the plus-maze test) at
both doses tested (50 and 100 mg/kg) (p>0.05). However, as shown in Fig. 20B pretreatment
with fenofibrate partially attenuated nicotinic somatic withdrawal signs only at the highest dose
used of 100 mg/kg (p<0.05). Somatic signs were expressed in the following distribution: paw
tremors (~70%), body tremors (~5%), head shakes (~10%), backing (~15%). Fenofibrate
partially attenuated these individual somatic signs in a uniformed manner. Lastly, as shown in
Fig. 20C pretreatment with fenofibrate was ineffective at attenuating the expression of
hyperalgesia (hot-plate latency) at both doses tested (p>0.05). The highest dose of fenofibrate
tested (100 mg/kg) did not significantly affect behavioral responses in saline infused mice in any
withdrawal test. In the nicotine withdrawal studies fenofibrate was administered at doses
previously described 291,292.
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Figure 20: Effects of PPARα Agonist Fenofibrate on Physical and Affective Signs of
Precipitated Nicotine Withdrawal.
Mice were chronically infused with saline or nicotine (24 mg/kg/day) for 14 days. On day
15mice received fenofibrate 1 hr pretreatment (50 and 100 mg/kg; i.p.) or vehicle. Withdrawal
was precipitated by administration of mecamylamine (2mg/kg; s.c.) 10 min prior to behavioral
testing of: A) anxiety-like behaviors (Time spent in the open arm); B) somatic signs; and C)
hyperalgesia (hot plate latency). Nicotine induced withdrawal symptoms increase anxietyrelated behavior and somatic signs, but decrease hot plate latency. Compared to vehicle,
pretreatment with fenofibrate: A) had no effect on the anxiety-like behavior; B) reduced somatic
signs at 100 mg/kg; and C) did not alter hot plate latency in nicotine withdrawn mice. Each point
represents the mean ± S.E.M. of 8 mice per group. * Denotes p< 0.05 vs. Saline MP group, #
Denotes p< 0.05 vs. Nicotine MP group
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PPARα Agonist Fenofibrate Did Not Alter Arm Crosses in the Elevated Plus Maze.
To examine whether or not the results observed in the elevated plus maze test was possibly
confounded by alterations in locomotor activity induced by fenofibrate administration, the
number of arm crosses were recorded. As shown in Table 6 fenofibrate did not
significantly alter the number of arm crosses in the plus maze test [F (5, 42) = 0.5318,
p = 0.7509].

91

Table 6: Fenofibrate does not have an effect on the average number of arm crosses in the
elevated plus maze test
Mice undergoing nicotine withdrawal received fenofibrate (50 and 100 mg/kg; i.p.) or vehicle.
The average number of arm crosses were recorded in the plus maze test. The numbers are
presented as the total number of arm crosses ± SEM (n=8).

Treatment

Average number of arm crosses ±SEM

Saline MP-vehicle

8.3± 0.6

Saline MP- Fenofibrate (50)

7.6±0.5

Saline MP- Fenofibrate (100)

7.4±0.3

Nicotine MP-vehicle

7.1±0.5

Nicotine MP-Fenofibrate (50)

7.8±0.5

Nicotine MP-Fenofibrate (100)

8±0.8
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D. Discussion
This is the first report demonstrating the ability of a PPARα antagonist to block the inhibitory
effects of an α7 nAChR agonist on nicotine reward in a mouse CPP paradigm (Fig. 12). This
suggests that α7 nAChR activation attenuates nicotine CPP in a PPARα-dependent mechanism.
We therefore compared the effects of a selective and potent PPARα agonist, WY-14643, to
fenofibrate, a clinically available PPARα agonist in nicotine mouse models of reward and
withdrawal. Our results provide some important and novel insights about the effects of PPARα
agonists in these nicotine dependence tests. The PPARα agonists WY-14643 and fenofibrate
attenuated nicotine preference as expected but fenofibrate was less potent (Fig. 13 and Fig.17).
In addition, the attenuation by fenofibrate in nicotine CPP was not PPARα-mediated (Fig.18).
Also, in contrast to WY-14643, fenofibrate had a modest efficacy in reducing nicotine
withdrawal signs (Fig. 19 and Fig. 20).
Our results indicated that attenuation by α7 nAChR activation in nicotine CPP is PPARα
mediated (Fig. 12). This finding is consistent with the suggestion that an α7 nAChR agonist
prevents nicotine-induced excitation of dopamine neurons via PPARα mechanism 116. Indeed, the
PPARα agonist WY-14643 completely and dose-dependently blocked nicotine conditioned
reward in the CPP test (Fig. 13). In addition, WY-14643 at the highest effective dose (1 mg/kg)
blocked all doses of nicotine in the CPP test (Fig. 15). Furthermore, WY-14643 (1mg/kg) had no
significant effect on cocaine CPP suggesting behavioral selectivity of WY-14643 for attenuating
nicotine reward (Fig.16). In support of our findings WY-14643 has been previously shown to be
ineffective in reducing cocaine self-administration

277

. Our findings with WY-14643 are

consistent with other PPARα agonists such as clofibrate that was reported to attenuate nicotine
reinforcement and reinstatement in rats through a PPARα mechanism of action
93

34,154,277

. Our

study with fenofibrate in nicotine CPP produced novel findings. Fenofibrate blocked the
development of nicotine CPP at a lower potency (a 9-fold difference estimate) than WY-14643,
the selective and potent PPARα agonist (Fig. 17). In fact, the dose of fenofibrate to completely
block nicotine CPP was 50mg/kg. At the higher dose of 100 mg/kg, fenofibrate-treated mice
were no longer statistically different from the nicotine-treated mice. Contrary to WY-14643,
fenofibrate blockade of nicotine preference was not PPARα-mediated. The PPARα antagonist
MK886, blocked the effects of WY-14643 but not fenofibrate in the nicotine CPP test (Fig. 14
and Fig.18). This is in contrast with the effects of another member of the fibrate family,
clofibrate, as well as other PPARα agonists such WY-14643 and methOEA in i.v. nicotine selfadministration and reinstatement models in rats and primates

34,277

. Indeed, the reduction of

nicotine reinforcement by these PPARα agonists was blocked by MK886. The lack of a PPARαdependency in the effect of fenofibrate is not entirely surprising since it has also been reported in
anti-proliferative and anti-inflammatory in vitro studies 300–303.
Our nicotine withdrawal results suggest PPARα activation by WY-14643 is effective at
attenuating nicotine withdrawal signs in a mouse model. To our knowledge this is the first study
to evaluate PPARα agonists in a preclinical test for nicotine withdrawal. WY-14643 attenuated
both the affective (anxiety-like behavior) and physical (somatic and hyperalgesia) signs of
withdrawal (Fig. 19) whereas fenofibrate only partially and modestly reduced the somatic signs
intensity at the highest dose used, 100 mg/kg (Fig. 20). Higher doses of fenofibrate were not
investigated due to adverse locomotor effects (data not shown). Clinically available smoking
cessation therapies act to a large extent by reducing the nicotine withdrawal signs/symptoms
82

, one of the primary causes of high tobacco relapse rates

29

; consequently, our animal studies

included a focus on nicotine withdrawal. Somatic signs have shown to contribute less to

94

nicotine-seeking behavior than affective signs 108,169; thus, the modest reduction of somatic signs
by fenofibrate may not predict its efficacy as a smoking cessation aid.
The α7 nAChR full agonist PNU282987 used in the CPP studies is selective for the α7 nAChR
248,304,305

. However, it has been suggested that α7 nAChR activation might indirectly lead to

downregulation of β2-nicotinic subunits via PPARα-induced phosphorylation of these subunits
116,278

. Indeed, α7 nAChR pharmacological activation by PNU282987 enhanced the neuronal

levels of endogenous PPARα ligands OEA and PEA in the VTA

116

. Therefore, PPARα

activation by WY-14643 may attenuate nicotine conditioned reward in the CPP test via a similar
mechanism leading to a functional downregulation of β2 subunits. β2-containing nAChRs are
well known to play an important role in nicotine reward in the CPP test 37.The lack of reduction
of cocaine CPP by PPARα agonist WY-14643 is somewhat surprising if we assume an important
role for β2-containing nAChRs in the effect of PPARα activation. Nevertheless, it is possible that
this mechanism (i.e. β2- containing nAChR downregulation) may not be involved in cocaine
CPP. Unlike nicotine CPP, genetic and pharmacological activation of α7 nAChRs does not alter
cocaine preference35. It has been reported that cocaine CPP is partially reduced in β2 knockout
mice298 at 5mg/kg of cocaine, suggesting that β2- containing nAChRs play a role in cocaine CPP.
However, at the higher dose of 10mg/kg, the dose used in our study, no reduction of cocaine CPP
was observed298. Another possibility is the degree of phosphorylation of the β2 subunit may not
be sufficient enough to alter cocaine CPP in comparison to a complete genetic ablation of the β2
subunit (β2 knockout mice). Therefore, the proposed mechanism of α7 nAChR activation
indirectly downregulating β2-containing nAChRs may not play a role in cocaine CPP. In
nicotine withdrawal, it is possible that regulation of β2 nAChR subunits influences the reversal
of nicotine withdrawal-related signs by the PPARα agonist WY-14643. Indeed, β2-containing
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nAChRs are important for the affective signs of nicotine withdrawal

93

. In addition, animal

studies reported a correlation between the time-course of brain β2-containing nAChRs
upregulation and nicotine withdrawal signs306. Furthermore, nicotine withdrawn smokers have
upregulated β2-containing nAChRs 195.
Collectively our preclinical findings on fenofibrate are consistent with its lack of effectiveness
seen in a recent clinical study

307

as a smoking cessation aid. The pilot study was a 4-week

evaluation of fenofibrate using a within-subjects crossover design with nicotine-dependent
volunteers (n=38). Although that experiment had limitations in sample size, duration and used
only one dose of fenofibrate, our data suggest that fenofibrate might not be the appropriate
PPARα drug to use because it has modest effects on nicotine withdrawal and has been shown to
be a weak and non-selective PPARα agonist (EC50 >10 μM)

294,295

. Importantly, our data with

WY-14643 and those reported with clofibrate34 suggests that PPARα is a potential molecular
target to evaluate for smoking cessation. Notably, PPARαs undergo different structural
conformations upon interaction with different ligands and each ligand-receptor conformation
may lead to different patterns of gene expression modulation. For example activation of PPARα
by WY-14643 and fenofibrate activate different set of genes as well a small set of overlapping
genes 308. Therefore, evaluation of more selective and potent PPARα agonists such as LY518674
(>2000-fold more potent and >300-fold more selective than fenofibrate) and PPARα biased
agonists such as the selective PPAR modulators (SPPARMS) K-877 (Pemafibrate®)

309

should

be considered. SPPARMS are thought to interact with the large binding pocket of PPARα to
induce a different co-factor recruitment, resulting in higher potency and fewer adverse side
effects than the original fibrate compounds

310

. LY518674 and K-877 are currently in phase II

trials with promising results in treating dyslipidemia
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311,312

. These compounds may prove to be

more efficacious candidates for smoking cessation therapy; however, preclinical studies are
imperative to investigate this hypothesis. In summary, our findings build on the understanding of
the underlying mechanism of α7 nAChR activation in nicotine reward. Further investigation
needs to be conducted to elucidate the role of PPARα mediation of α7 nAChR in nicotine
dependence.
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CHAPTER FOUR

Investigating the Role of Ethanolamides in Nicotine Dependence
A. Introduction

Our results from the previous chapter suggested that fenofibrate, a PPARα agonist currently
used to reduce high cholesterol levels, might not be an efficacious treatment for nicotine
dependence. Fenofibrate reduced nicotine reward in the CPP test at the high dose of 50mg/kg in
a non-PPARα mediated manner. In addition, fenofibrate showed a very modest efficacy on
nicotine withdrawal. Our results with fenofibrate are in agreement with a clinical study that
showed fenofibrate was ineffective as a smoking cessation aid 307. We suggested that this lack of
efficacy in rodents and human testing is probably due to the fact that fenofibrate is weak and
non-selective activator of PPARα

295,313 295,314

. In addition, PPARα expression in the brain is

lower than in other organs such as the liver where it induces its lipolysis effects

287,315

. This

suggests that attenuation of nicotine dependence may require the use of higher potency and
efficacy PPARα agonists. Indeed, in the previous chapter, we showed that in contrast to
fenofibrate, the potent and selective PPARα agonist WY-14643 attenuated nicotine CPP in a
PPARα-dependent manner and reversed nicotine withdrawal signs in our models. Thus, PPARα
may still be a viable target for smoking cessation but it is clear fenofibrate is not a desirable
PPARα agonist to use.
The nuclear receptor PPARα is a transcription factor that mediates the transcription of genes
involved in inflammation and lipolysis
associated with reward

287–289

276

. Of importance, PPARαs are located in brain regions

and activated by endogenous ligands OEA and PEA. Recent
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evidence showed that exposure to nicotine may regulate the endogenous PPARα system. For
example, a reduction in the levels of the endogenous PPARα agonist OEA was observed in the
VTA dialysate of rats under a nicotine i.v. self-administration regimen

316

, suggesting that the

ethanolamide deficit may contribute to nicotine dependence. Therefore, correcting this deficit by
enhancing the levels of endogenous PPARα agonist may be a potential approach to treat nicotine
dependence.
Direct administration of OEA and PEA to activate PPARα may be one possible strategy. It
has been previously shown that methOEA (a long-lasting analog of OEA) reduces the rewarding
effect of nicotine in intravenous self-administration after systemic administration in rats

277

.

Although providing proof of principle, utilizing natural lipids as therapeutic agents has
limitations. such as fast metabolism, poor pharmacokinetic properties upon oral ingestion in
humans 317,318. Inhibiting the degradative enzymes of OEA and PEA may serve as an alternative
strategy to increase endogenous OEA and PEA activity at PPARα. Indirect activation of a
receptor bypasses overstimulation of the system, which attenuates unintended side effects. In
addition, inhibiting the degradative enzyme instead of direct OEA/PEA administration restricts
the effect of the drug only to locations that possess that particular enzyme which also reduces
unwanted side effects that may be caused by widespread activation of OEA/PEA targets after
their administration. This is a similar approach that has been used in the cannabinoid field where
indirect activation of cannabinoid receptors, by inhibiting degradative enzymes such as FAAH
and MAGL, has been shown to produce more therapeutic benefits and bypass some negative side
effects of direct agonists201,319. OEA and PEA are enzymatically degraded by FAAH and the
lysosomal enzyme N-acylethanolamine hydrolyzing acid amidase (NAAA)

320,321

which are

enzymes that differ in their catalytic mechanisms, structure, and selectivity for substrates. Both

99

enzymes have been shown to enhance OEA and PEA levels

320,322,323

, but inhibition of FAAH

also increases AEA levels, one of the endogenous cannabinoids. FAAH has more selectivity for
AEA in comparison to PEA and OEA, whereas NAAA is more selective for PEA than AEA

321

.

Therefore, the inhibition of FAAH is not a favorable approach to enhance OEA and PEA levels
in hopes of reducing the rewarding effect of nicotine. NAAA is expressed in regions of the brain
associated with reward along with PEA, OEA, and PPARα
enhances OEA and PEA levels

325

287,289,321,324

. NAAA inhibition

, and both OEA and PEA have been shown to block nicotine-

induced VTA dopaminergic neuron excitation in a PPARα dependent manner

115

. Thus we

hypothesize that NAAA inhibition will indirectly activate PPARα which in turn will reduce
nicotine reward. The novel and selective NAAA inhibitor AM9053 322 and AM11095, its analog
with a better pharmacokinetic profile, were examined in the nicotine CPP test. AM9053 has
been shown to potently inhibit NAAA (IC50=30nM) and enhance OEA and PEA levels under
naïve and inflammatory conditions

322,326

. NAAA inhibitors are typically used in pain-related

studies, however the utilization of these compounds in nicotine reward may provide insight on
the role of ethanolamides in nicotine dependence.

.
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Figure 21: Schematic of Degradation of OEA and PEA (Adapted from 317)
The fatty acid ethanolamides OEA and PEA exert their effects primarily through PPARα. OEA and PEA
are inactivated by the hydrolase NAAA into fatty acid and ethanolamine. The novel AM9053 compound
selectively inhibits NAAA.
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Figure 22: Structure of AM9053 (Structure provided by Dr. Alexandros Makriyannis’ lab)
AM9053 inhibits NAAA activity with an IC50 value of 30nM. AM9053 showed a remarkable
selectivity for human NAAA as compared to endocannabinoid serine hydrolase FAAH >100 uM
322
.
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B. Materials and Methods
Animals

Drug-naive, ICR male mice (8 weeks old upon arrival; Harlan Laboratories, Indianapolis, IN)
served as subjects. Mice were housed four per cage with ad libitum access to food and water on a
12-h light cycle in a humidity and temperature controlled vivarium that was approved by the
Association for Assessment and Accreditation of Laboratory Animal Care. Mice received corn
cob bedding and were fed Envigo Teklad mouse/rat diet 7102 (LM-485). Experiments were
performed during the light cycle and were approved by the Institutional Animal Care and Use
Committee of Virginia Commonwealth University and followed the National Institutes of Health
Guidelines for the Care and Use of Laboratory Animals.

Drugs
(−)-Nicotine hydrogen tartrate [(−)-1-methyl-2-(3- pyridyl) pyrrolidine (+)-bitartrate] was
purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA). AM9053 and AM11095 were gifts
from Dr. Alexandros Makriyannis of Northeastern University. AM9053 was dissolved in a
mixture of 1:1:18 [1 volume ethanol/1 volume Emulphor-620 (Sanofi-Aventis, Bridgewater, NJ)
and 18 volumes distilled water]. AM11095 was dissolved in a mixture of 1:1:18 [1 volume
ethanol/1 volume Tween-80 (Sigma-Aldrich Co., St. Louis, MO) and 18 volumes distilled water]
. Nicotine was injected s.c. and dissolved in saline. AM9053 and AM11095 were administered
i.p. The nicotine solution pH was neutralized with sodium bicarbonate as needed. Freshly
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prepared solutions were given to mice at 10 ml/kg. Doses are expressed as the free base of the
drug.
Nicotine and Cocaine conditioned place preference studies

An unbiased CPP paradigm was performed. Briefly, the CPP apparatus consisted of three
chambers in a linear arrangement (Med Associates, St Albans, VT). The CPP apparatus
(MedAssociates, St. Albans, VT, ENV3013) consisted of white and black chambers (20×20×20
cm each), which differed in overall color and floor texture (white mesh or black rod). These
chambers were separated by a smaller gray chamber with a smooth PVC floor. Partitions could
be removed to allow access from the gray chamber to the black and white chambers. On day 1,
animals were confined to the middle chamber for a 5-min habituation and then allowed to freely
move between all three chambers for 15 min. Time spent in each chamber was recorded, and
these data were used to populate groups of approximately equal bias in baseline chamber
preference. Twenty-minute conditioning sessions occurred twice a day (days 2–4). During
conditioning sessions, mice were confined to one of the larger chambers. The saline groups
received saline in one large chamber in the morning and saline in the other large chamber in the
afternoon. The drug group received drug in one large chamber and saline in the other large
chamber. Treatments were counterbalanced equally in order to ensure that some mice received
the unconditioned stimulus in the morning while others received it in the afternoon. The
nicotine-paired chamber was randomized among all groups. Sessions were 4 h apart and were
conducted by the same investigator. On each of the conditioning days, mice were pretreated
with AM9053(i.p.), AM11095(i.p.) or its vehicle 2 hr or 1hr prior to nicotine injection
respectively. On test day (day 5), mice were allowed access to all chambers for 15 min in a drug
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free state. The preference score was calculated by determining the difference between the time
spent in the drug paired side during test day versus the time in drug paired side during the
baseline day.

Statistical analysis
Data were analyzed using the GraphPad software version 6.0 (GraphPad Software, Inc., La Jolla,
CA) and expressed as the mean ± S.E.M. A one-way analysis of variance (ANOVA) in
conjunction with Holm-Šídák comparison tests were conducted to determine significant effects
of drug treatments vs controls. Comparisons were considered statistically significant when p <
0.05.
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C. Results

Development of Nicotine CPP Attenuated by NAAA Inhibitor AM9053
Mice were conditioned with either saline or nicotine (0.5 mg/kg; s.c.) for 3 days in the CPP
paradigm. In Fig. 23 a robust CPP was observed in nicotine–conditioned mice pre-treated with
vehicle [F(4, 30) = 7.990, p=0.0002]. AM9053 given 2 hr prior to nicotine reduced nicotine
reward. As revealed by the Holm-Šídák comparison tests, AM9053 (3mg/kg) significantly
altered nicotine CPP (p<0.05), but was ineffective at the lower dose of 1 mg/kg (p>0.05).
AM9053 at the highest dose used (3 mg/kg) did not produce a preference or aversion in saline
treated-mice.
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Figure 23. The Effect of NAAA Inhibitor AM9053 on Nicotine CPP.
Mice were conditioned with either s.c. saline or nicotine (0.5mg/kg) for 3 days. A robust CPP
was observed in nicotine-conditioned mice pre-treated with vehicle. AM9053 (1 and 3mg/kg;
i.p.) reduced nicotine reward as measured by the CPP test.*Denotes p<0.05 from vehicle control;
# Denotes p<0.05 from nicotine control. Each point represents the mean ± SEM of n=6-8 mice
per group.
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Development of Nicotine CPP Attenuated by NAAA Inhibitor AM11095
Mice were conditioned with either saline or nicotine (0.5 mg/kg; s.c.) for 3 days in the CPP
paradigm. In Fig. 24 a robust CPP was observed in nicotine–conditioned mice pre-treated with
vehicle [F(4, 32) = 6.490, p=0.0006]. AM11095 given 1 hr prior to nicotine reduced nicotine
reward. As revealed by the Holm-Šídák comparison tests, AM11095 (5mg/kg) significantly
altered nicotine CPP (p<0.05), but was ineffective at the lower dose of 1mg/kg (p>0.05).
AM11095 at the highest dose used (5 mg/kg) did not produce a preference or aversion in saline
treated-mice.
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Figure 24. The Effect of NAAA Inhibitor AM11095 on Nicotine CPP
Mice were conditioned with either s.c. saline or nicotine (0.5mg/kg) for 3 days. A robust CPP
was observed in nicotine-conditioned mice pre-treated with vehicle. AM11095 (1 and 5mg/kg;
i.p.) reduced nicotine reward as measured by the CPP test. * Denotes p<0.05 from vehicle
control; # Denotes p<0.05 from nicotine control. Each point represents the mean ± SEM of n=68 mice per group.

109

D. Discussion
The present study is the first to report the impact of the pharmacological inhibition of the
lysosomal enzyme NAAA, degradative enzyme for OEA and PEA, in nicotine reward. Our
results show that NAAA inhibition by AM9053 and AM11095 attenuates nicotine preference.
AM9053 was shown to be highly selective and potent (IC50 = 30nM) in vitro for NAAA
blockade and has efficacy in an in vivo murine model of colitis

322

and attenuated expression of

inflammatory markers caused by lipopolysaccharide-induced macrophage activation326. AM9053
increases PEA and OEA levels after repeated administration in vivo or 8 hr incubation in vitro
322,326

. AM9053 enhances the levels of OEA and PEA in control J774 macrophage cells326.

AM9053 has also been shown to increase the levels of other ethanolamides such as
stearoylethanolamide, AEA, and docosahexaenoylethanolamide

326

; however, OEA was

increased to a greater extent. After systemic administration, AM9053 not only enhanced PEA
levels in the colon but the liver as well 322. In addition, it has been shown that AM9053 does not
enhance cerebellum PEA levels in mice with trinitrobenzene sulfonic acid-induced colitis322. The
efficacy of AM11095 and its effect on ethanolamide levels is not available. There are reports that
suggest NAAA inhibitors mediate anti-inflammatory and antinociceptive effects in animal
models of pain and inflammation

322,323,327

through a PPARα-mediated mechanism325,328. Thus,

our findings in nicotine CPP are consistent with the premise that NAAA inhibition indirectly
activates PPARα. PPARα activation reduces nicotine reward and reinforcement154,329 in rodents
and nonhuman primates. In addition, it has been previously shown that methOEA (a long-lasting
analog of OEA) reduces the rewarding effect of nicotine in the intravenous self-administration
after systemic administration in rats 277. In addition, OEA and PEA block nicotine-induced VTA
110

dopaminergic neuron excitation in a PPARα dependent manner

115

. Additional studies will

further the understanding of the ethanolamide system in nicotine dependence
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CHAPTER FIVE
GENERAL DISCUSSION
A. Rationale
Tobacco use is one of the leading causes of preventable deaths in the world5. There are current
smoking cessation aids available; however, these therapies are modestly successful with less than
30% of users remaining abstinent for more than 1 year

15

. Therefore, there is a need for more

efficacious therapies and this need may be met by a better understanding of the molecular
underpinnings that induce nicotine dependence. Nicotine, the main addictive component in
tobacco, exerts its effects through nAChRs

108

. One of the most abundant nAChRs in the brain,

the homomeric α7 nAChR, has unique features and its role in nicotine dependence is not well
understood. α7 nAChRs rapidly desensitize, have a low probability of being open
calcium permeability
reward

30,35

50
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and high

. Preclinical data suggests that α7 nAChR activation attenuates nicotine

and pharmacological/genetic blockade of α7 nAChR enhances nicotine reward and

reinforcement

30,35

. The characteristics of the α7 nAChR and its complex circuitry (see Ch.1

Section F and Fig. 1 for details) may account for these behavioral observations. Thus, the first
aim of this dissertation was to investigate the impact of desensitization and channel opening of
α7 nAChRs using pharmacological modulators such as PAMs and a silent agonist.
As previously mentioned, the α7 nAChR with its high calcium permeability induces signaling
pathways that have been implicated in the areas of pain and cognition. With the interesting
findings for the behavioral data, we sought to investigate a possible signaling cascade activated
by α7 nAChR that may further elucidate its role in nicotine dependence. Therefore, the second
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aim of this dissertation sought to elucidate a possible mechanism underlying the α7 nAChR by
investigating PPARα as a downstream mediator of the α7 nAChR..
B. Summary of Results
Chapter 2 focused on aim 1 by elucidating the effects of α7 nAChR conformational changes in
nicotine reward and withdrawal by utilizing pharmacological interventions. α7 nAChR
orthosteric agonist PNU282987, Type I PAM NS1738, Type II PAM PNU120596, and the silent
agonist NS6740 were used. The α7 full orthosteric agonist PNU282987 and the Type II α7
nAChR PAM PNU120596 reduced nicotine CPP (Fig. 4 and 6) while the silent agonist NS6740
and Type I PAM NS1738 had no effect (Fig. 5 and 7). In nicotine withdrawal, PNU282987,
NS1738, and PNU120596 attenuated different aspects of the withdrawal syndrome (Fig.8, 9 and
10). In the nicotine withdrawal experiments the orthosteric agonist PNU282987 attenuated
anxiety-like behaviors (Fig.8); however, the α7 nAChR PAMs NS1738 and PNU120596 had no
effect on anxiety-like behavior as observed in the elevated plus maze (Fig. 9 and 10). The
orthosteric full agonist PNU282987 and they Type I PAM NS1738 both attenuated somatic
signs, but the Type II PAM PNU120596 had no effect on somatic signs. PNU120596 was the
only ligand to reduce hyperalgesia. To our knowledge, this is the first report of α7 nAChR PAMs
and a silent agonist used in preclinical nicotine dependence tests. The results from chapter 2
highlighted the importance of α7 nAChR desensitization, probability of channel opening, and
endogenous tone.
The next chapter (Chapter 3) focused on aim 2 and investigated a potential mediator of the α7
nAChR, PPARα. This chapter suggests that α7 nAChR activation attenuates nicotine CPP in a
PPARα-dependent mechanism (Fig.12). In addition, the PPARα agonists WY-14643 and
fenofibrate attenuated nicotine preference as expected but fenofibrate was less effective and not
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PPARα-dependent (Fig. 13, Fig.17 and Fig.18). In addition, in contrast to WY-14643,
fenofibrate had a modest efficacy in reducing nicotine withdrawal signs (Fig.19 and Fig.20).
Chapter 4 is a continuation of the theme of Chapter 3, but with an emphasis on indirect activation
of PPARα. This is a short chapter on the inhibition of NAAA, the degradative enzyme for OEA
and PEA, in nicotine reward. The results show that NAAA inhibition attenuates nicotine
preference in mice (Fig.23 and Fig.24), which is consistent with the premise that NAAA
inhibition indirectly activates PPARα.
C. Discussion of Results
Collectively, these results suggest that the role α7 nAChR in nicotine dependence is
conformation-dependent and mediated by PPARα. The finding in Chapter 2 that the silent
agonist NS6740 has no effect on nicotine CPP (Fig.7) is similar to its lack of effect in a
preclinical model of cognitive function245. This suggests ion conductance/receptor activation is
necessary for the α7 nAChR induced reduction of nicotine CPP. This result also supports the role
of PPARα mediation in the effect of the α7 nAChR, as suggested in Chapter 3. Indeed, α7
nAChR pharmacological activation by PNU282987 enhanced the neuronal levels of endogenous
PPARα ligands OEA and PEA in the VTA in a Ca2+-dependent manner

116

. However, if the

notion of the necessity of channel activation is valid, it is unclear why the α7 nAChR Type I
PAM NS1738 (1 and 10mg/kg) was ineffective at reducing nicotine CPP. NS1738 increases the
probability of opening of α7 nAChRs. The increase in channel opening would increase the
likelihood of ion conductance, thus it is plausible that NS1738 would be more effective than the
orthosteric agonist PNU282987 at attenuating nicotine CPP. Higher doses of NS1738 than those
used in our current study have been effective in inflammation studies240 and may also induce an
effect in nicotine CPP.
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In addition, this dissertation is the first to utilize α7 nAChR PAMs in nicotine CPP and
withdrawal. The results suggests the presence of an endogenous tone mediated through α7
nAChRs that modulates nicotine reward and withdrawal. The Type I PAM NS1738 attenuated
nicotine withdrawal-induced somatic signs (Fig. 9). The Type II PAM PNU120596 attenuated
nicotine CPP (Fig. 6) and nicotine withdrawal-induced hyperalgesia (Fig. 10). The modulation of
the endogenous tone is receptor conformation dependent. In particular, these findings may
suggest that individuals with low endogenous α7 nAChR activation are more likely to develop
nicotine dependence. This dissertation adds to the understanding of the endogenous cholinergic
system in nicotine dependence.
The neurotransmitter systems of the brain such as glutamate, GABA, dopamine, and
acetylcholine have been implicated in aspects of nicotine dependence. Nicotine targets nAChRs
and induces its dependency effects. The β2* nAChRs are required for nicotine reward,
reinforcement and some aspects of withdrawal

93,135,183

. Nicotine has a low affinity for the α7

nAChR and initial preclinical studies suggested that this receptor was not involved in the
rewarding effects induced by nicotine

37

. However, recently it has been shown that the α7

nAChR modulates nicotine reward 30,35. This may be due to its neurophysiological modulation of
neurotransmitter systems involved in nicotine dependence. The locality of α7 nAChRs on
presynaptic terminals and postsynaptically allow this receptor to modulate neurotransmitter
release and participate in fast synaptic transmission. The circuitry of the α7 nAChR in the
mesolimbic system provides multiple possible pathways the α7 nAChR can modulate dopamine
release (Fig. 1). For instance, the preterminal α7 nAChRs on glutamatergic afferents in the NAc
potentiate glutamate release and are synapsed on to medium spiny neurons. Activation of these
α7 nAChRs can indirectly activate ionotropic glutamate receptors on dopaminergic axon
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terminals

221,222

which results in dopamine release. However, if preterminal α7 nAChRs were

desensitized the net outcome would be a reduction of dopamine release. Another potential
outcome of preterminal α7 nAChR activation on glutamatergic axon terminals in the NAc is
attenuation of dopamine release via activation of metabotropic glutamate receptor activation. 223.
This outcome will result in enhancement of dopamine release if α7 nAChRs are desensitized.
The results from Ch.2 of this dissertation may provide a behavioral understanding of α7 nAChRs
in nicotine dependence, but it does not aid in determining which pathways are activated or
desensitized. The attenuation of nicotine CPP by the Type II PAM PNU120596, which increases
the probability of channel opening and blocks desensitization, may suggest that through delayed
desensitization or resensitization of an α7 nAChR-mediated inhibitory pathway on dopamine was
activated. In addition, the effect of PNU120596 is dependent on the endogenous
acetylcholine/choline tone. Thus, enough endogenous tone was provided for PNU120596 to
induce an effect. The lack of effect of the silent agonist NS6740 may suggests that this ligand
desensitized an inhibitory α7 nAChR pathway. Further molecular and behavioral studies may
elucidate the role of α7 nAChR circuitry in nicotine dependence.
The PPARα and α7 nAChR interaction may occur at postsynaptical α7 nAChRs in the VTA on
dopaminergic neurons

218,330

. PPARα is a nuclear hormone receptor that is predominately found

in the nucleus or the surrounding cytoplasmic space

295,331,332

. Furthermore, the ethanolamides

OEA, PEA, and the endocannabinoid AEA are made on demand and are thought to be
synthesized by a membrane bound enzyme
retrograde transmission

333

320

. AEA is released postsynaptically to engage in

thus, it is reasonable to believe that AEA is synthesized in the soma

along with other ethanolamides such as OEA and PEA. Interestingly, it has been suggested that
mice lacking the α7 nAChR showed a steady increase in nicotine induced dopamine outflow
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over time in the nucleus accumbens which was in contrast to WT mice 256. This may suggest that
α7 nAChRs serve as an inhibitory regulator of dopamine release in the VTA. It has been
previously postulated that α7 nAChRs may modulate β2* nAChR-induced dopamine release via
PPARα in the VTA116,278. Indeed, nicotine-induced dopamine release is β2* nAChR
dependent135. Further physiological and behavioral studies are needed to understand this
interaction.

D. Future Directions
The overall future directions of this dissertation are to elucidate the neurocircuitry and
pharmacology of α7 nAChRs and PPARα in nicotine CPP and withdrawal, in hopes to implicate
these receptors as viable targets for smoking cessation aids. The pharmacological ligands used in
this

dissertation were

systemically

administered;

therefore, local

infusions

of

the

pharmacological ligands administered in nicotine CPP and nicotine withdrawal will aid in
determining the neurocircuitry involved. NAAA, PPARα, and α7 nAChRs are expressed in brain
regions associated with reward such as the prefrontal cortex, NAc and VTA
Also, these regions are involved in nicotine CPP

36,139,336

41,122,289,321,334,335

.

. Genetically modified mice such as

floxed α7 nAChR mice337 may provide an understanding of the neural substrates involved. Even
though CPP and self-administration were originally thought to be isomorphic models for
measuring drug reward, it is now accepted that CPP measures drug reward and selfadministration measures drug reinforcement

71

. Thus to further extend the understanding of our

finding in nicotine dependence, it is important to test the mechanisms in this dissertation in
nicotine intravenous self-administration and reinstatement. Furthermore, SPPARMS for PPARα
such as K-877309 may have a higher potency than original fibrate compounds because they
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interact with the large binding pocket of PPARα to induce a different co-factor recruitment310.
Therefore, it is important to test SPPARMS in nicotine dependence assays.
In addition, we will continue to characterize the NAAA inhibitors in nicotine CPP by
investigating the PPARα mediation of its effects. OEA and PEA have other targets such as Gprotein-coupled receptor 55, transient receptor potential cation channel subfamily V member,
and G-protein-coupled receptor 119

338–340

. Administering OEA and PEA systemically in

nicotine dependence assays will further implicate ethanolamides in nicotine dependence. Also,
the effect of NAAA inhibition in nicotine withdrawal will provide more evidence of the
involvement of the ethanolamide system in nicotine dependence.
There is a dire need for new molecular targets for smoking cessation therapies. The β2*
nAChRs have been extensively studied and are the targets for some of the current therapies.
However, given the modest efficacy of the current smoking cessation aids, it suggest the need for
new molecular targets. This dissertation focused on the α7 nAChR and PPARα as potential new
targets for smoking cessation aids. Our work and others suggest that the α7 nAChR may act as a
molecular break that attenuates nicotine rewarding effects produced by high affinity nAChR
subtypes. Therefore, selectively activating α7 nAChRs may reduce the rewarding effects of
nicotine even in individuals who are currently using tobacco products. α7 nAChR agonists and
modulators are undergoing clinical trials to enhance cognitive function, thus, these ligands can
be repurposed as smoking cessation aids 341,342. In addition, this dissertation suggests that PPARα
mediates the attenuation of α7 nAChRs in nicotine CPP. Also, activation of this receptor has
been previously shown to attenuate nicotine reward and reinforcement. Furthermore, this
dissertation is the first to report PPARα activation attenuates nicotine withdrawal signs. The K877 SPPARM for PPARα is undergoing clinical trials309 and can also be repurposed as a
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smoking cessation aid. Taken together the results from this dissertation aids support the
development of α7 nAChR agonists and more potent PPARα activators such as K-877 as
possible smoking cessation aids.

119
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Mentor, Professional and Personal Development Class 2016
Mentor, Big Brothers and Big Sisters Organization, 2015-2016
Secretary, Social Justice Ministry, Sixth Mount Zion Baptist Church, 2016-2017
Student Representative, Virginia Commonwealth University, Department Retreat Committee 2016
Conference Manager, Georgia State University Housing, 2013
Resident Assistant, Georgia State University Housing, 2012-2013
Secretary, Georgia State University, Beta Beta Beta Biological Honor Society 2012-2013

Research Publications
Jackson A, Bagdas D, Muldoon P ,Lichtman A, Carroll FI, Greenwald M, Miles M, and Damaj MI (2017) In vivo
Interactions between α7 Nicotinic Acetylcholine Receptor and Nuclear Peroxisome Proliferator-Activated
Receptor- α: Implication for Nicotine Dependence. Neuropharmacology 118:38-45
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Slater C., Jackson A.*, Muldoon P., Dawson A., O'Brien M., Soll L., Abdullah R., Carroll FI, Tapper A., Miles M.,
Banks M, Damaj MI (2016) Nicotine Enhances the Hypnotic and Hypothermic Effects of Alcohol in the Mouse.
Alcohol: Clinical and Experimental Research 40(1):62-72 *co-first author
Alsharari SD, King JR, Nordman JC, Muldoon PP, Jackson A, Zhu AZ, Tyndale RF, Kabbani N, Damaj MI. (2015)
Effects of Menthol on Nicotine Pharmacokinetic, Pharmacology, and Dependence in Mice. PLoS One
10(9):e0137070
Bowers MS, Jackson A, Muldoon P, Damaj MI (2016). N-acetylcysteine decreased nicotine reward-like properties
and withdrawal in mice. Psychopharmacology 233(6):995-1003
Carroll FI, Navarro HA, Mascarella SW, Castro AH, Luetje CW, Wageman CR, Marks MJ, Jackson A, Damaj
MI.(2015) In Vitro and in Vivo Neuronal Nicotinic Receptor Properties of (+)- and (-)-Pyrido[3,4]homotropane
[(+)- and (-)-PHT]: (+)-PHT is a Potent and Selective Full Agonist at α6β2 Containing Neuronal Nicotinic
Acetylcholine Receptors. ACS Chemical Neuroscience 6(6):920-6
Enga R, M, Jackson A, Damaj MI, Beardsley PM (2016) Oxycodone physical dependence and its oral selfadministration in C57BL/6J mice. European Journal of Pharmacology 789:75-80
Jackson KJ, Jackson A, Ivy Carroll F, Damaj MI (2015) Effects of orally-bioavailable short-acting kappa opioid
receptor-selective antagonist LY2456302 on nicotine withdrawal in mice. Neuropharmacology 97:270-4

Professional Oral Presentations
Jackson A., and Damaj M. (2016) Investigating the Role of Peroxisome Proliferator-Activated Receptor Type-α in
Nicotine Dependence. Carolina Cannabinoid Collaborative Meeting in Philadelphia, PA
Jackson A., and Damaj M. (2014) Investigating the Genetics of Nicotine Dependence Using Mouse Models.
Virginia Commonwealth University Biomedical Sciences Doctoral Portal in Richmond, VA

Professional Poster Presentations
Jackson A., Bagdas D., Muldoon P., Lichtman A., Carroll FI, Miles M. and Damaj M. (2016). Investigating the
Role of the α7 Nicotinic Acetylcholine Receptors in Nicotine Dependence. Society for Neuroscience in San
Diego, CA
Jackson A., Muldoon P., Damaj M. (2016) The Role of the α7 Nicotinic Acetylcholine Receptor in Nicotine
Dependence. Chemistry and Pharmacology of Drugs of Abuse Conference in Boston, MA
Jackson A., Bagdas D., Damaj M. (2016) Investigating the Role of the α4β2 Nicotinic Receptor Positive
Allosteric Modulator Desformylflustrabromine in Nicotine Dependence. Virginia Brain Rx Symposium in
Richmond, VA
Jackson A., Muldoon P., Damaj M. (2015) Nicotine Reward Modulated by α7 Nicotinic Acetylcholine Receptor
and Peroxisome Proliferator-Activated Receptor α Interaction. Mid-Atlantic PREP/IMSD Research Symposium
in Raleigh, NC
Jackson A., Alsharari S., Siu E., Tyndale R., Kabbani N., Damaj M. (2015) Effects of Menthol on Nicotine
Pharmacokinetic, Pharmacology, and Dependence in Mice. Society for Research on Nicotine and Tobacco
Meeting in Philadelphia, PA
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Jackson A., Muldoon P., Damaj M. (2014) Peroxisome Proliferator-Activated Receptor Type-α Agonists as New
Treatments for Nicotine Dependence. Carolina Cannabinoid Collaborative Meeting in Winston-Salem, NC
Jackson A., Slater C., Muldoon P., Damaj M., (2013) Acute and Chronic Nicotine-Ethanol Interaction in the Loss
of Righting Reflex Test. Research Colloquium at Virginia Commonwealth University in Richmond, VA
Jackson A., Polites J., Williams B., Frantz K., (2012) Comparison of Locomotor Activity in Adolescent and
Adult Male Rats during Cocaine Self-Administration. Annual Biomedical Research Conference for Minority
Students Conference in San Jose, CA
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